רÀûÃû³Æ£ºÒ»ÖÖɸѡ¿¹ÌåµÄ·½·¨
¼¼ÊõÁìÓò£º
±¾·¢Ã÷Éæ¼°Ò»ÖÖɸѡ¿¹ÌåµÄ·½·¨¡£
±³¾°¼¼Êõ£º
½èÖúµ°°×չʾ¼¼ÊõµÄ¸ßͨÁ¿¿¹ÌåɸѡÒѾ³ÉΪÏÖÔÚ¿¹ÌåÖÆ±¸µÄÖ÷Òª·½·¨Ö®Ò»¡£ ÊɾúÌåչʾ¼¼Êõ¡¢ºËÌÇÌåչʾ¼¼ÊõºÍ½Íĸչʾ¼¼ÊõÒѾ±»¹ã·ºµÄÓ¦ÓÃÓÚп¹ÌåµÄɸѡºÍ ¿¹ÌåÇ׺ÍÁ¦µÄ¸Ä½ø¡£Õ¹Ê¾µÄ¿¹ÌåÄÜÓëÄ¿µÄ¿¹Ô½áºÏ´Ó¶ø±»¿ìËٵĴӸ´ÔӵĿ¹ÌåÎÄ¿âÖРɸѡ³öÀ´¡£Í¨³£ÓÃÓÚ¿¹ÌåɸѡµÄ¿¹ÔÊÇÒÑÖªµÄ¿ÉÈÜÐÔ´¿»¯¿¹Ô¡£È»¶øÐí¶à¼²²¡µÄ·Ö×Ó ±ê¼Ç¶¼¶¨Î»ÓÚϸ°ûĤ±íÃæ£¬²¢ÇÒ¾ßÓи´ÔӵķÒëºóÐÞÊΣ¬ÀýÈçÌÇ»ù»¯(Ohtsubo K, Marth JD :Glycosylation in cellular mechanisms of health and disease. Cell 2006£¬ 126(5) :855-867.)¡£ÌÇ»ù»¯¶ªÊ§»áÓ°Ïìµ°°×µÄÕÛµþЧÂʺÍÎȶ¨ÐÔ(Shental-Bechor D£¬ Levy Y :Folding of glycoproteins toward understanding the biophysics of the glycosylation code. Curr Opin Struct Biol 2009£¬19 (5) :524_533¡¤)¡£²¢ÇÒÐí¶à°©Ï¸ °û±íÃæµÄÌÇ»ù»¯¶¼ÓÐÃ÷ÏԱ仯(Kim YJ, Varki A !Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997£¬14(5) 569-576.)¡£¿ÉÊÇͨ¹ýÉúÎ﹤³Ì¼¼Êõ½øÐÐÉú²úºÍ´¿»¯µÄ¿ÉÈÜÐÔ¿¹Ôͨ³£»á¶ªÊ§·Òëºó ÐÞÊΣ¬ÎÞ·¨ÕæÊµ·´Ó³ÌìÈ»¿¹ÔµÄ¹¹Ïó(Liat Binyamina HBaLMW Cancer therapy with engineered monoclonal antibodies Update on Cancer Therapeutics 2006,1 (2) 147-157. Linenberger ML,Maloney DG,Bernstein ID :Antibody_directed therapies for hematological malignancies. Trends Mol Med 2002,8(2) :69_76.)¡£¶øÇÒÓÐʱ¿¹ÔÊÇδ ÖªµÄ·Ö×Ó£¬ÎÞ·¨»ñµÃ´¿»¯µÄ¿¹Ô¡£Òò´ËÈç¹ûÄÜÒÔÍêÕûϸ°ûΪ¿¹ÔÉ¸Ñ¡ÌØÒì½áºÏϸ°û±íÃæ¿¹ ԵĿ¹Ì壬²ÅÓÐÀûÓÚɸѡµ½Ê¶±ðÌìÈ»¿¹Ô±íλµÄп¹Ì壬½«¸ü¼ÓÓÐÀûÓÚÁÙ´²µÄÕï¶ÏºÍÖÎÁÆ¡£µ½Ä¿Ç°ÎªÖ¹£¬ÊɾúÌåչʾϵͳºÍ½Íĸչʾϵͳ¶¼Òѱ»Ö¤Ã÷Äܹ»Ö±½ÓÒÔÍêÕûµÄϸ°û ×÷Ϊ¿¹Ô£¬É¸Ñ¡ÌØÒìʶ±ðϸ°û±íÃæ¿¹ÔµÄ¿¹Ìå¡£µ«ÊÇÊɾúÌåչʾ¼¼ÊõÓÉÓÚչʾЧÂÊÓÐÏÞ£¬²» ÊÇËùÓеÄÐòÁж¼ÄÜÔÚÊɾúÌåÖлñµÃºÜºÃµÄ±í´ï¡£¶øÇÒÔÚÊɾúÌåÀ©ÔöµÄ¹ý³ÌÖУ¬ÓÉÓÚ²åÈëÆ¬ ¶ÎÐÔÖʵIJ»Í¬£¬¿ÉÄܳÊÏÖ³öÉú³¤²îÒ죬´Ó¶ø¿ÉÄܶªÊ§ÎÄ¿â¶àÑùÐÔ¡£´ËÍ⣬ÊɾúÌåչʾϵͳÄÑ ÒÔչʾ·Ö×ÓÁ¿½Ï´óµÄµ°°×£¬Òò´Ë²»Äܳɹ¦Õ¹Ê¾ÍêÕûµÄIgG¿¹Ìå·Ö×Ó¡£¶ø½Íĸչʾ¼¼ÊõÓÉÓÚ Êܵ½×ª»¯Ð§ÂʵÄÓ°Ï죬ºÜÄѹ¹½¨×ã¹»´óµÄ¿¹ÌåÎĿ⡣ͨ³£ÎÄ¿â´óС< 108¡£Ï¸¾úÔÉúÖÊÌåչʾ¼¼Êõ(APEx) (Harvey BR, Georgiou G, Hayhurst A, Jeong KJ, Iverson BL, Rogers GK Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 2004,101(25) :9193_9198.)ÊÇÒ»ÖÖ¸ßЧµÄϸ¾úչʾ ¼¼Êõ¡£APExչʾ¼¼ÊõÊǽ«µ°°×Öʱí´ï¶¨Î»µ½Ï¸¾úÖÜÖʿռäÖУ¬µ°°×ÖÊͨ¹ýN¶ËÈںϵÄÄÚĤ Ö¬µ°°×NlpAµÄÁù¸ö°±»ùËáÐòÁÐ(CDQSSS)ÒÔ¹²¼Ûõ¥»¯µÄ·½Ê½Ãª¶¨ÔÚÄÚĤÍâ²à£¬»òÕßÊÇͨ¹ý C¶ËÈںϵÄM13ÊɾúÌåÍâ¿Çµ°°×3 (g3p)µÄN¶ËƬ¶Ï궨ÔÚÄÚĤÖУ¬´Ó¶ø½«Ä¿µÄµ°°×չʾµ½ ÖÜÖʿռ䡣Ȼºó¿ÉÒÔͨ¹ýEDTAºÍÈܾúøµÄ×÷Óý«Ï¸¾úµÄÍâĤȥµô£¬´Ó¶ø½«ÄÚĤÉÏ궨µÄµ°°×Öʱ©Â¶³öÀ´¡£±©Â¶µÄ¿¹Ìå¿ÉÒÔºÍÓ«¹â±ê¼ÇµÄ¿¹Ô½áºÏ´Ó¶øÊ¹Ï¸¾ú»ñµÃÃ÷ÏÔµÄÓ«¹â¡£Í¨¹ý Á÷ʽ·ÖÑ¡¿ÉÒÔ½«ÌØÒì½áºÏ¿¹ÔµÄϸ¾ú·ÖÑ¡³öÀ´£¬´Ó¶ø»ñµÃÏàÓ¦µÄ¿¹Ìå¡£APExչʾϵͳ¾ßÓÐÐí¶àÓŵ㡣(I)APExչʾϵͳÊÇÒ»ÖÖϸ¾úչʾϵͳ£¬ÈÝÒ×¹¹½¨ ¾Þ´óµÄ¿¹ÌåÎÄ¿â(> IO9)¡£(2)궨·½Ê½¶àÑù£¬¿ÉÒÔÑ¡ÔñC¶Ë»òN¶Ë궨¡£(3)ÓÉÓÚ¿¹ÌåÕ¹ ʾÔÚÄÚĤ±íÃæ£¬¶øÄÚĤ²»º¬ÓÐLPS»òÆäËü¸´ÔӵĶàÌÇÀàµÈÍâĤµÄ³É·Ý£¬±íÃæÏà¶ÔƽÕûÒò´Ë ²»»á¶Ô´ó·Ö×Ó¿¹ÔÓ뿹ÌåµÄ½áºÏ²úÉú¿Õ¼äÓ°Ïì¡£Òò´Ë£¬APExϵͳչʾµÄ¿¹Ìå¿ÉÓÐЧµÄ½áºÏ ·Ö×ÓÁ¿¸ß´ï240kDaµÄ¿ÉÈÜÐÔ¿¹Ô¡£(4)¿¹ÌåµÄչʾֻÐèÒª´©¹ýÒ»²ãϸ°ûĤ£¬¶ø²»ÐèÒªÏñ½Í ĸչʾ»òϸ¾úÍâĤչʾϵͳÄÇÑùÒª´©Ô½Ï¸°ûÍâ±Ú£¬ÕâʹµÃ¿¹ÌåµÄչʾ²»»áÊÜ·Ö×ÓÁ¿ºÍ¿Õ¼ä ½á¹¹µÄÏÞÖÆ£¬Õ¹Ê¾Ð§¹û¸üºÃ¡£Òò´Ë£¬APExϵͳÄܹ»³É¹¦µØÕ¹Ê¾ÍêÕûµÄIgG¿¹Ìå(Mazor Y,Van Blarcom ¦³, Mabry R, Iverson BL, Georgiou G :Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007, 25(5) :563-565.)¡£²¢ÇÒÍêÕûµÄIgG¿¹Ìå¾ßÓÐÁ½¸ö¿¹Ô½áºÏλµã£¬¿ÉÒÔ²úÉú¶þ¼Û½áºÏ£¬Õ⽫ ÓÐÀûÓÚɸѡµ¥¼Û½áºÏÇ׺ÍÁ¦½ÏµÍµÄ¿¹Ìå¡£(5)¿ÉÒÔÖ±½ÓÀûÓù㷺ʹÓõÄÊɾúÌåÕ¹Ê¾ÔØÌåÀ´ ½øÐе°°×±í´ï£¬ÕâʹµÃ¿ÉÒÔÖ±½ÓÀûÓÃÐí¶àÊɾúÌåչʾµÄµ¥Á´¿¹ÌåµÄÎÄ¿â×ÊÔ´¡£
·¢Ã÷ÄÚÈÝ
±¾·¢Ã÷µÄÒ»¸öÄ¿µÄÊÇÌṩһÖÖɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ·½·¨¡£±¾·¢Ã÷ËùÌṩµÄɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ °û£»2)½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдý ɸѡµ°°×µÄϸ¾úÔÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ ÓÚËùÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔ µÄÏ໥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ½«ËùÊö½áºÏÎï´Ó·õ ÓýÌåϵÖзÖÀë³öÀ´£»4)´Ó²½Öè3)µÃµ½µÄ½áºÏÎïÖзÖÀëµÃµ½ÓëչʾÓÚÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ÌØÒìÐÔ ½áºÏµÄÄ¿µÄµ°°×»òÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£ÉÏÊöɸѡ·½·¨ÖУ¬ËùÊö´ýɸѡµ°°×¿âΪº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ýɸѡ µ°°×¿â¡£¼´¸Ã·½·¨ÊʺÏÓÚº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ýɸѡµ°°×¿â¡£ÉÏÊöɸѡ·½·¨ÖУ¬´ýɸѡµ°°×¿â¿ÉÒÔÊÇÏÖÓеÄÓÃÓÚÊɾúÌåչʾ¼¼ÊõµÄ¿ÉɸѡµÄµ° °×¿â£¬Ò²¿ÉÒÔÊÇÏÖÓеİüº¬¸ü´óµÄ¿¹Ìå(ÀýÈçÍêÕûµÄIgG)µÄµ°°×¿â¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨ËùÊö·õÓýÌåϵ µÄ PH ֵΪ 5. 0-7. 5£¬¾ßÌåΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0,7. 3,7. 5¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Î¶ÈΪ 30-37¡ãC£¬¾ßÌåΪ30¡ãC»ò37¡ãC £»Ê±¼äΪ0. 5-2Сʱ£¬¾ßÌåΪ0. 5h»òIh»ò2h¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖÐ·Ö Àë³öÀ´µÄ·½·¨°üÀ¨£¬Ê×ÏÈʹÓÃÆ½°åÌÔÑ¡·¨É¸Ñ¡£¬È»ºóʹÓÃÁ÷ʽ·ÖÑ¡·¨·ÖÑ¡¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬Ê¹ÓÃÁ÷ʽ·ÖÑ¡·¨µÄ²½ÖèΪÊ×ÏÈ´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδͬËùÊöÕæºËϸ°ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔÉúÖÊÌ壬ÔÙͨ¹ýÁ÷ʽϸ°ûÒÇɸѡ£¬ÊÕ¼¯Ëù ÊöÕæºËϸ°ûÓëÔÉúÖÊÌå·¢ÉúÌØÒìÐÔ½áºÏµÄ½áºÏÎï¡£ÉÏÊöÁ÷ʽϸ°ûÒÇɸѡ·½·¨ÖУ¬ËùÊö´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδÐγɽáºÏÎïµÄϸ¾úÔ ÉúÖÊÌåµÄ·½·¨Îª½«ËùÊö·õÓýµÄÌåϵ300gÀëÐÄ1. 5-3·ÖÖÓºó£¬ÊÕ¼¯³Áµí£¬ÆúÈ¥ÉÏÇå¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖзÖÀë³öÀ´µÄ·½·¨ ÖУ»ÌÔÑ¡·¨ÎªÔÚÆ½°åÉÏÌÔÑ¡¿É½áºÏµÄϸ¾úÔÉúÖÊÌ壬ËüÖ÷ÒªÊÇÒ»ÖÖ¶¨ÐÔµÄɸѡ£¬ÊǰÑÄܹ»½á ºÏµÄϸ¾úÔÉúÖÊÌ嶼ɸѡ³öÀ´£¬¶ø²»ÊǸù¾Ý½áºÏÁ¦Ç¿ÈõÀ´½øÐÐɸѡ¡£¶øÁ÷ʽϸ°û·ÖÑ¡¼¼Êõ ÊÇÒ»ÖÖ¾ßÓиßͨÁ¿£¬¶à²ÎÊý¶¨Á¿·ÖÑ¡ÄÜÁ¦µÄ¼¼Êõ£¬ËüÄܹ»¸ù¾ÝÇ׺ÍÁ¦Ç¿Èõ½øÐж¨Á¿µÄɸѡ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊö½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ °ûĤ±íÃæÊÇÓɰüÀ¨Èçϲ½ÖèµÄ·½·¨ÖƱ¸µÃµ½µÄ½«º¬ÓÐËùÊöÄ¿±êµ°°×±àÂë»ùÒòµÄÖØ×éÔØÌå תÈëËùÊöÕæºËϸ°ûÖУ¬µÃµ½ÖØ×éÕæºËϸ°û£¬ÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í ´ï£¬µÃµ½ËùÊö±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»ËùÊöÕæºË±í´ïÔØÌå¿ÉÒÔÊÇÈκοÉÔÚÕæºËϸ°ûĤ±íÃæÕ¹Ê¾µÄÔØÌå¡£ÓÅÑ¡ÊÇ pUHD10-3-display(SEQ ID :6)£¬¸ÃÔØÌåÊǰ´ÕÕÈçÏ·½·¨µÃµ½µÄ½«DNAƬ¶Î²åÈëpUHD10_3 ÔØÌåÖÐËÄ»·Ëص÷¿ØµÄÆô¶¯×ÓÏÂÓεÄEcoR IºÍXba IÖ®¼ä£¬µÃµ½ÖмäÖØ×éÔØÌ壻ÔÙ½«ËùÊöÄ¿ ±êµ°°×µÄ±àÂë»ùÒò²åÈëËùÊöÖмäÖØ×éÔØÌåµÄBgl IIºÍSal Iλµã¼ä£¬µÃµ½ËùÊöÄ¿±êµ°°×µÄ ±àÂë»ùÒòµÄÖØ×éÔØÌ壻ËùÊöDNAƬ¶ÎµÄÐòÁÐÈçÏÂËùʾ£¬ÖƱ¸·½·¨ÎªÒÔÔØÌåpDisplayΪģ°å£¬ÓÃÈçÏÂÒýÎï ¶Ô½øÐÐPCRÀ©ÔöµÃµ½µÄÉÏÓιØÎïACGCGAATTCGCCACCATGGAGACAGACACACTCCTGCTÏÂÓιØÎïAACTAGTCTAGACTAACGTGGCTTCTTCTGCCAAAGCAT¡£ËùÊöÕæºËϸ°û¿ÉÒÔÊÇCH0¡¢C0Sl¡¢C0S7¡¢293T¡¢HeLa¡¢HCT116µÈ£¬ÓÅÑ¡ÊÇH1299ϸ°ûÖê¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊöÄ¿±êµ°°×µÄ±àÂë»ùÒòÊÇÈËÔ´»¯ µÄ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè2)ÖУ¬½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾ ÓÚϸ¾úÔÉúÖÊÌå±íÃæµÄ·½·¨°üÀ¨Èçϲ½Ö轫´ýɸѡµ°°×µÄ±àÂë»ùÒò²åÈëϸ¾ú±í´ïÔØÌå ÖУ¬µÃµ½±í´ïËùÊö´ýɸѡµ°°×µÄÖØ×éÔØÌ壬½«ËùÊö±í´ï´ýɸѡµ°°×µÄÖØ×éÔØÌåתÈëËÞÖ÷ϸ ¾ú£¬µÃµ½ÖØ×éϸ¾ú£¬ÅàÑøËùÊöÖØ×éϸ¾ú²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬ÔÙÌáÈ¡ÖØ×éϸ¾úµÄÔÉú ÖÊÌ壬µÃµ½ËùÊö±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔÉúÖÊÌå¡£ËùÊöµÄϸ¾úÖл¹¿ÉÒÔתÈëÓÃÓÚͨ¹ýÓ«¹âÐźÅɸѡÔÉúÖÊÌåµÄÓ«¹âµ°°×±í´ïÔØÌ壬 ¸ÃÔØÌå¿ÉÒÔÊÇÔÚϸ¾úÖбí´ïÈκÎÑÕɫӫ¹âµ°°×ÖʵÄÔØÌ壬ÓÅѡΪPBAD30-KmR-GFPmut2¡£ËùÊöµÄϸ¾ú¿ÉÒÔÊǸ÷Öִ󳦸˾úÈçDH10B£¬Topl0£¬JM109£¬BL21µÈ£¬ÓÅѡΪ´ó³¦¸Ë ¾ú Jude-IÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè4)ÖУ¬ËùÊö´Ó½áºÏÎïÖзÖÀëµÃµ½Ä¿µÄµ°°×»ò Ä¿µÄµ°°×µÄ±àÂë»ùÒòµÄ·½·¨°üÀ¨Èçϲ½Öè´ÓËùÊö½áºÏÎïÖÐÌáÈ¡ËùÊö±í´ïÄ¿µÄµ°°×µÄÖØ×é ÔØÌ壬½«ÖØ×éÔØÌå½øÐвâÐò£¬µÃµ½ËùÊöÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£Êµ¼ÊÓ¦ÓÃÖУ¬ËùÊöÄ¿±êµ°°×¿ÉΪ¿¹Ô£¬ËùÊö´ýɸѡµ°°×¿ÉΪ¿¹Ì壻ËùÊö¿¹Ìå¾ßÌå¿É ÎªÌØÒìʶ±ðÈËԴϸ°û±íÃæ¿¹ÔµÄ¿¹Ìå¡£
±¾·¢Ã÷µÄÁíÒ»¸öÄ¿µÄÊÇÌṩһÖÖʹÓÃÉÏÊö·½·¨¸¨Öú¼ø¶¨µ°°×ÊÇ·ñÓëÄ¿±êµ°°×½á ºÏµÄ·½·¨¡£±¾·¢Ã÷ËùÌṩµÄ¸¨Öú¼ø¶¨µ°°×ÊÇ·ñÓëÄ¿±êµ°°×½áºÏµÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæ ºËϸ°û£»2)½«´ý¼ø¶¨µ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдý ¼ø¶¨µ°°×µÄϸ¾úÔÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ ÓÚËùÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔ µÄÏ໥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ¼ì²â·õÓýµÄÌåϵÖÐ ÊÇ·ñº¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÈôº¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×ÓëËùÊöÄ¿±êµ° °×½áºÏ£¬Èô²»º¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×²»ÓëËùÊöÄ¿±êµ°°×½áºÏ¡£ÉÏÊö¼ø¶¨·½·¨ÖУ¬ËùÊö´ý¼ø¶¨µ°°×¿âΪº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ýɸѡ µ°°×¿â¡£¼´¸Ã·½·¨ÊʺÏÓÚº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ý¼ø¶¨µ°°×¿â¡£ÉÏÊö¼ø¶¨·½·¨ÖУ¬´ý¼ø¶¨µ°°×¿â¿ÉÒÔÊÇÏÖÓеÄÓÃÓÚÊɾúÌåչʾ¼¼ÊõµÄ¿ÉɸѡµÄµ° °×¿â£¬Ò²¿ÉÒÔÊÇÏÖÓеİüº¬¸ü´óµÄ¿¹Ìå(ÀýÈçÍêÕûµÄIgG)µÄµ°°×¿â¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨ËùÊö·õÓýÌåϵ µÄ PH ֵΪ 5. 0-7. 5£¬¾ßÌåΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0,7. 3,7. 5¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Î¶ÈΪ30-37¡ãC ºÍʱ¼äΪ0. 5-2Сʱ¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬¼ì²â·õÓýµÄÌåϵÖÐÊÇ·ñº¬ÓÐËùÊöÌØÒì ÐÔ½áºÏÎïµÄ·½·¨ÊÇÁ÷ʽϸ°ûÒǼì²â¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬¿É½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖзÖÀë ³öÀ´ÔÙ½øÐмì²â£¬·ÖÀë·½·¨°üÀ¨£¬Ê×ÏÈʹÓÃÆ½°åÌÔÑ¡·¨É¸Ñ¡£¬È»ºóʹÓÃÁ÷ʽ·ÖÑ¡·¨·ÖÑ¡¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬Ê¹ÓÃÁ÷ʽ·ÖÑ¡·¨µÄ²½ÖèΪÊ×ÏÈ´ÓËùÊö·õÓýÌåϵÖÐÈ¥ ³ýδͬËùÊöÕæºËϸ°ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔÉúÖÊÌ壬ÔÙͨ¹ýÁ÷ʽϸ°ûÒÇɸѡ£¬ÊÕ¼¯Ëù ÊöÕæºËϸ°ûÓëÔÉúÖÊÌå·¢ÉúÌØÒìÐÔ½áºÏµÄ½áºÏÎï¡£ÉÏÊöÁ÷ʽϸ°ûÒÇɸѡ·½·¨ÖУ¬ËùÊö´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδÐγɽáºÏÎïµÄϸ¾úÔ ÉúÖÊÌåµÄ·½·¨Îª½«ËùÊö·õÓýµÄÌåϵ300gÀëÐÄ1. 5-3·ÖÖÓºó£¬ÊÕ¼¯³Áµí£¬ÆúÈ¥ÉÏÇå¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖзÖÀë³öÀ´µÄ·½·¨ ÖУ»ÌÔÑ¡·¨ÎªÔÚÆ½°åÉÏÌÔÑ¡¿É½áºÏµÄϸ¾úÔÉúÖÊÌ壬ËüÖ÷ÒªÊÇÒ»ÖÖ¶¨ÐÔµÄɸѡ£¬ÊǰÑÄܹ»½á ºÏµÄϸ¾úÔÉúÖÊÌ嶼ɸѡ³öÀ´£¬¶ø²»ÊǸù¾Ý½áºÏÁ¦Ç¿ÈõÀ´½øÐÐɸѡ¡£¶øÁ÷ʽϸ°û·ÖÑ¡¼¼Êõ ÊÇÒ»ÖÖ¾ßÓиßͨÁ¿£¬¶à²ÎÊý¶¨Á¿·ÖÑ¡ÄÜÁ¦µÄ¼¼Êõ£¬ËüÄܹ»¸ù¾ÝÇ׺ÍÁ¦Ç¿Èõ½øÐж¨Á¿µÄɸѡ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊö½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ °ûĤ±íÃæÊÇÓɰüÀ¨Èçϲ½ÖèµÄ·½·¨ÖƱ¸µÃµ½µÄ½«º¬ÓÐËùÊöÄ¿±êµ°°×±àÂë»ùÒòµÄÖØ×éÔØÌå תÈëËùÊöÕæºËϸ°ûÖУ¬µÃµ½ÖØ×éÕæºËϸ°û£¬ÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í ´ï£¬µÃµ½ËùÊö±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»ËùÊöÕæºË±í´ïÔØÌå¿ÉÒÔÊÇÈκοÉÔÚÕæºËϸ°ûĤ±íÃæÕ¹Ê¾µÄÔØÌå¡£ÓÅÑ¡ÊÇ pUHD10-3-display(SEQ ID :6)£¬¸ÃÔØÌåÊǰ´ÕÕÈçÏ·½·¨µÃµ½µÄ½«DNAƬ¶Î²åÈëpUHD10_3ÔØÌåÖÐËÄ»·Ëص÷¿ØµÄÆô¶¯×ÓÏÂÓεÄEcoR IºÍXba IÖ®¼ä£¬µÃµ½ÖмäÖØ×éÔØÌ壻ÔÙ½«ËùÊöÄ¿ ±êµ°°×µÄ±àÂë»ùÒò²åÈëËùÊöÖмäÖØ×éÔØÌåµÄBgl IIºÍSal Iλµã¼ä£¬µÃµ½ËùÊöÄ¿±êµ°°×µÄ ±àÂë»ùÒòµÄÖØ×éÔØÌ壻ËùÊöDNAƬ¶ÎµÄÐòÁÐÈçÏÂËùʾ£¬ÖƱ¸·½·¨ÎªÒÔÔØÌåpDisplayΪģ°å£¬ÓÃÈçÏÂÒýÎï ¶Ô½øÐÐPCRÀ©ÔöµÃµ½µÄÉÏÓιØÎïACGCGAATTCGCCACCATGGAGACAGACACACTCCTGCTÏÂÓιØÎïAACTAGTCTAGACTAACGTGGCTTCTTCTGCCAAAGCAT¡£ËùÊöÕæºËϸ°û¿ÉÒÔÊÇCH0¡¢C0Sl¡¢C0S7¡¢293T¡¢HeLa¡¢HCT116µÈ£¬ÓÅÑ¡ÊÇH1299ϸ°ûÖê¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊöÄ¿±êµ°°×µÄ±àÂë»ùÒòÊÇÈËÔ´»¯ µÄ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè2)ÖУ¬½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾ ÓÚϸ¾úÔÉúÖÊÌå±íÃæµÄ·½·¨°üÀ¨Èçϲ½Ö轫´ýɸѡµ°°×µÄ±àÂë»ùÒò²åÈëϸ¾ú±í´ïÔØÌå ÖУ¬µÃµ½±í´ïËùÊö´ýɸѡµ°°×µÄÖØ×éÔØÌ壬½«ËùÊö±í´ï´ýɸѡµ°°×µÄÖØ×éÔØÌåתÈëËÞÖ÷ϸ ¾ú£¬µÃµ½ÖØ×éϸ¾ú£¬ÅàÑøËùÊöÖØ×éϸ¾ú²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬ÔÙÌáÈ¡ÖØ×éϸ¾úµÄÔÉú ÖÊÌ壬µÃµ½ËùÊö±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔÉúÖÊÌå¡£ËùÊöµÄϸ¾úÖл¹¿ÉÒÔתÈëÓÃÓÚͨ¹ýÓ«¹âÐźÅɸѡÔÉúÖÊÌåµÄÓ«¹âµ°°×±í´ïÔØÌ壬 ¸ÃÔØÌå¿ÉÒÔÊÇÔÚϸ¾úÖбí´ïÈκÎÑÕɫӫ¹âµ°°×ÖʵÄÔØÌ壬ÓÅѡΪPBAD30-KmR-GFPmut2¡£ËùÊöµÄϸ¾ú¿ÉÒÔÊǸ÷Öִ󳦸˾úÈçDH10B£¬Topl0£¬JM109£¬BL21µÈ£¬ÓÅѡΪ´ó³¦¸Ë ¾ú Jude-I ¦ÏÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè4)ÖУ¬ËùÊö´Ó½áºÏÎïÖзÖÀëµÃµ½Ä¿µÄµ°°×»ò Ä¿µÄµ°°×µÄ±àÂë»ùÒòµÄ·½·¨°üÀ¨Èçϲ½Öè´ÓËùÊö½áºÏÎïÖÐÌáÈ¡ËùÊö±í´ïÄ¿µÄµ°°×µÄÖØ×é ÔØÌ壬½«ÖØ×éÔØÌå½øÐвâÐò£¬µÃµ½ËùÊöÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£Êµ¼ÊÓ¦ÓÃÖУ¬ËùÊöÄ¿±êµ°°×¿ÉΪ¿¹Ô£¬ËùÊö´ý¼ø¶¨µ°°×¿ÉΪ¿¹Ì壻ËùÊö¿¹Ìå¾ßÌå¿É ÎªÌØÒìʶ±ðÈËԴϸ°û±íÃæ¿¹ÔµÄ¿¹Ìå¡£±¾·¢Ã÷µÄÁíÒ»¸öÄ¿µÄÊÇÌṩһÖÖÓÃÓÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄÊÔ¼ÁºÐ¡£±¾·¢Ã÷ËùÌṩµÄÓÃÓÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄÊÔ¼ÁºÐ£¬ÓÉÕæºËϸ°û¡¢Õæ ºËϸ°û±í´ïÔØÌå¡¢ÓÃÓÚÖÆ±¸ÔÉúÖÊÌåµÄϸ¾ú¡¢ÔÉúÖÊÌåÕ¹Ê¾ÔØÌå¡¢ÔÚÔÉúÖÊÌåÖбí´ïÓ«¹âµ° °×ÒÔ±ãÓÚɸѡµÄÔØÌå×é³É¡£ÉÏÊöÊÔ¼ÁºÐÖУ¬ËùÊöÀëÌåÈËԴϸ°ûΪÈË·ÇСϸ°û·Î°©Ï¸°ûÖêH1299 £»ËùÊöÕæºËϸ °û±í´ïÔØÌåΪpUHD10-3-display(SEQ ID 6)£»ËùÊöϸ¾úΪ´ó³¦¸Ë¾ú¾úÖêJude-I £»ËùÊö±í´ï Ó«¹âµ°°×µÄÔØÌåΪpBAD30-KmR-GFPmut2¡£Ï¸¾úÔÉúÖÊÌåչʾ·½·¨ÔÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×ÖеÄÓ¦ÓÃÒ²ÊôÓÚ±¾·¢ Ã÷µÄ±£»¤·¶Î§¡£±¾·¢Ã÷ÌṩÁËÀûÓÃAPExչʾ¼¼ÊõÓ¦ÓÃÓÚÒÔÍêÕûµÄÈËϸ°ûΪ¿¹ÔÉ¸Ñ¡ÌØÒìʶ±ðÈË Ï¸°û±íÃæ¿¹ÔµÄ¿¹ÌåµÄÒ»ÖÖɸѡ·½·¨¡£APExϸ¾úչʾϵͳӵÓÐÓëÊɾúÌåչʾϵͳÏ൱´óС µÄ¿¹Ìå¿â(áêIO9)£¬²¢ÇÒ¾ßÓÐչʾÍêÕûµÄIgG¿¹ÌåµÄÄÜÁ¦¡£´ËÍâAPExϸ¾úչʾϵͳ¿ÉÒÔÖ± ½ÓÀûÓù㷺ʹÓõÄÊɾúÌå±í´ïÔØÌå½øÐе°°×չʾ£¬Òò´Ë¿ÉÒÔÖ±½ÓÀûÓÃÏÖÓеÄÊɾúÌåµ¥Á´¿¹ ÌåÎÄ¿â½øÐÐɸѡ¡£´Ë·½·¨µÄ½¨Á¢£¬ÓÐÖúÓÚɸѡ¸ü¶àʶ±ðϸ°û±íÃæ·Ö×Ó±ê¼ÇµÄ¿¹Ì壬¶Ô¼²²¡Õï
8¶ÏºÍÖÎÁƶ¼½«Æðµ½¾Þ´óµÄÍÆ¶¯×÷Óá£
ͼ1Ϊӫ¹âÏÔ΢¾µ¹Û²ìºÍÁ÷ʽϸ°ûÒÇ·ÖÎöH1299_tet on-PAD4ϸ°û±íÃæPAD4µÄ±í´ï¡£Í¼2Ϊӫ¹âÏÔ΢¾µ¹Û²ìϸ¾úÔÉúÖÊÌåÓëÌù±Úϸ°ûµÄ½áºÏ¡£Í¼3ΪH1299_tet on-PAD4ϸ°ûÓëչʾ¿¹ÌåM18µÄϸ¾úÔÉúÖÊÌåµÄÌØÒì½áºÏ¡£Í¼4ΪpHÖµ¶Ôչʾ¿¹ÌåM18µÄϸ¾úÔÉúÖÊÌåÓëH1299_tet on_PAD4ϸ°û½áºÏµÄÓ°Ï졣ͼ5ΪչʾM18¿¹ÌåµÄϸ¾úÔÉúÖÊÌåÔÚ²»Í¬³õʼ´¿¶Èʱ±»Æ½°åÌÔÑ¡ºÍÁ÷ʽ·ÖÑ¡µÄ
¸»¼¯Ð§ÂÊ¡£Í¼6Ϊ¶àÂÖ¸»¼¯Õ¹Ê¾M18¿¹ÌåµÄϸ¾úÔÉúÖÊÌå¡£
¾ßÌåʵʩÀý·½Ê½±¾·¢Ã÷ÓÃÒÑÓеĿ¹Ô-¿¹Ìå¶Ô×÷ΪģÐÍ£¬Ö¤Ã÷չʾÁËÌØ¶¨¿¹ÌåµÄϸ¾úÔÉúÖÊÌ壬 Äܹ»Í¨¹ýÓëÈËϸ°û±íÃæÕ¹Ê¾µÄ¿¹ÔÏ໥×÷ÓôӶø½áºÏµ½Ï¸°û±íÃæ¡£Ñ¡ÓÃÁËÌ¿¾Ò¸Ë¾ú±£»¤ ¿¹ÔµÄÒ»¸öƬ¶ÏPA domaiM×÷Ϊ¿¹Ô£¬¶ø¶ÔÓ¦µÄµ¥Á´¿¹ÌåΪM18 ScFv0¶ø¿¹µØ¸ßÐÁ±êÇ© (DIG)µÄµ¥Á´¿¹Ìå26-10 scFv×÷ΪÒõÐÔ¶ÔÕÕ¡£½«ÓÕµ¼ºóµÄH1299-tet on-PAD4ϸ°û´Óƽ°å ÉÏø½âÏÂÀ´£¬È»ºó·Ö±ðºÍչʾ¿¹PAD4µÄµ¥Á´¿¹Ìå»ò¿¹DIG±êÇ©µÄµ¥Á´¿¹Ìå²¢´øÓÐGFPmut2 Ó«¹âµÄϸ¾úÔÉúÖÊÌå·õÓý¡£·õÓýÍêºó£¬È¥µôδ½áºÏµÄϸ¾úÔÉúÖÊÌå¡£½«Ï¸°ûÖØÐüºóÔÚÁ÷ʽ ϸ°ûÒÇÉϼì²â¡£ÓÉÓÚϸ°ûºÍϸ¾úÔÉúÖÊÌåÔÚ´óСÉÏÓÐÃ÷ÏÔ²î±ð£¬ÔÚÁ÷ʽϸ°ûÒÇÉÏ¿ÉÒÔͨ¹ý ǰÏòÉ¢Éä¹âFSCºÍ²âÏòÉ¢Éä¹âSSCÐźÅÃ÷ÏÔµÄÇø·Ö¿ª¡£H1299ϸ°ûÔÚÁ÷ʽϸ°ûÒÇÉϳÊÏÖ±È Ï¸¾úÔÉúÖÊÌå¸ü´óµÄFSCºÍSSCÐźţ¬¿ÉÒÔ׼ȷµÄѡȡϸ°ûȺ£¬·ÖÎöϸ°ûÒòΪ½áºÏÁËÓÐÓ«¹â µÄϸ¾úÔÉúÖÊÌå¶ø»ñµÃµÄGFPÓ«¹â¡£Ó«¹âµÄÇ¿Èõ¾ÍÄÜ·´Ó³³öϸ¾úÔÉúÖÊÌå½áºÏµÄÇ¿Èõ¡£ÏÂÊöʵʩÀýÖÐËùʹÓõÄʵÑé·½·¨ÈçÎÞÌØÊâ˵Ã÷£¬¾ùΪ³£¹æ·½·¨¡£ÏÂÊöʵʩÀýÖÐËùÓõIJÄÁÏ¡¢ÊÔ¼ÁµÈ£¬ÈçÎÞÌØÊâ˵Ã÷£¬¾ù¿É´ÓÉÌҵ;¾¶µÃµ½¡£ÊµÊ©Àý1¡¢É¸Ñ¡¿¹ÌåµÄ·½·¨Ò»¡¢½«¿¹ÔPAD4չʾÓÚÀëÌåµÄ¶¯Îïϸ°û±íÃæÈË·ÇСϸ°û·Î°©Ï¸°ûÖêH1299ϸ°û¹º×ÔÖйúҽѧ¿ÆÑ§ÔºÖ×Áöϸ°û¿â£¬²úƷĿ¼ºÅ Ϊ 0092¡£pUHDlO-3ÔØÌåÔÚÎÄÏ×(Gossen M, Bujard H :Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992,89(12) :5547_5551.)Öй«¿ª¹ý¡£(Domain 4 of the Anthrax Protective Antigen gene)°×É×IS Âë»ùÒòÐòÁÐÈçSEQ ID N0:5Ëùʾ¡£ÈËϸ°ûmRNA·Òë³£ÓõÄÃÜÂë×ÓÓëϸ¾úÓÐËù²îÒ죬ÈËÔ´»¯ ¸ÃDNAµÄÄ¿µÄÊÇΪÁËÈËϸ°ûµÄ·Òë»úÆ÷ÄܸßЧµØ·Òë¸Ã»ùÒòת¼³öÀ´µÄmRNA¡£pDisplay(¹º×ÔInvitrogen)ÊDz¸È鶯Îïϸ°û±í´ïÔØÌ壬רÃÅÓÃÓÚ½«ÖØ×éµ°°×¶¨ λÓÚ²¸È鶯Îïϸ°ûĤ±íÃæ¡£Í¨¹ý½«¸ÐÐËȤµÄ»ùÒò¿Ë¡µ½ÔØÌå¿ò¼Ü(°üÀ¨N¶ËIg k·ÖÃÚÐÅ ºÅ£¬C ¶ËѪС°åÀ´Ô´µÄÉú³¤Òò×ÓÊÜÌå(PDGFR) (Gronwald RG, Grant FJ, Haldeman ¦¢¦¡, HartCE, Of Hara PJ, Hagen FS,Ross R,Bowen-Pope DF, Murray MJ :Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor :evidence for more than one receptor class. Proc Natl Acad Sci USA 1988,85(10) :3435_3439.) µÄ¿çĤ궨ÓòÖУ¬¶øÊ¹±í´ïµÄµ°°×Öʶ¨Ïò궨ÓÚϸ°û±íÃæ¡£PAD4ͨ¹ýC¶ËÓëѪС°åÀ´Ô´µÄ Éú³¤Òò×ÓÊÜÌå(PDGFR)µÄ¿çĤ궨ÓòÈÚºÏÔÚN¶Ë·ÖÃÚÐźŵÄÒýµ¼Ï´ӶøÄܹ»Õ¹Ê¾µ½H1299 ϸ°ûĤ±íÃæ¡£ÒÔ pDisplay Ϊģ°å£¬ÓÃÒýÎï¶Ô(ÉÏÓÎÒýÎï ACGCGAATTCGCCACCATGGAGACAGACACACTC CTGCT£¬ÏÂÓιØÎï AACTAGTCTAGACTAACGTGGCTTCTTCTGCCAAAGCAT)½øÐÐ PCR À©Ôö£¬À©Ôö²úÎïÖÐ °üÀ¨ÔØÌåÉϵÄIg kÁ´Ç°µ¼ÐòÁÐ(·ÖÃÚÐźÅ)¡¢HA±êÇ©¡¢¶à¿Ë¡λµãÇø¡¢c-myc±êÇ©¼°PDGFR ¿çÄ¤Çø¡£½«PCRÀ©Ôö²úÎï²åÈëpUHD10-3ÔØÌåÖÐËÄ»·Ëص÷¿ØµÄÆô¶¯×ÓÏÂÓεÄEcoR IºÍXba IÖ®¼ä£¬µÃµ½¹¹½¨ÕýÈ·µÄÖØ×éÖÊÁ££¬¼Ç×÷pUHD10-3-displayÔØÌå¡£¸ÃpUHDlO-3-displayÔØ ÌåÖÐͨ¹ýËÄ»·ËØÀ´µ÷½ÚÍâÔ´µ°°×(PAD4)ÔÚϸ°û±íÃæµÄ±í´ï¡£ÓÃoverlap PCRµÄ·½·¨ºÏ³ÉÈËÔ´»¯µÄPAD4 DNAÐòÁУ¬¾ßÌåÈçÏÂ×é×°PAD4µÄ¹IÎïÐòÁÐ1 TCAGagatctCGGTTCCACTATGATCGGAACAACATCGCAGTCG 342 TGAGCTTCCTTCACGACGCTTTCGTCTGCGCCGACTGCGATGTTGTTCCG 503 GCGTCGTGAAGGAAGCTCACCGGGAAGTGATCAACAGCAGCACTGAAGGA 504 CGAATATCCTTATCGATGTTCAGGAGGAGTCCTTCAGTGCTGCTGTTGAT 505 CCTCCTGAACATCGATAAGGATATTCGGAAGATTCTGAGCGGCTACATCG 506 TTTGAGTCCCTCAGTATCTTCGATCTCCACGATGTAGCCGCTCAGAATCT 507 AGATCGAAGATACTGAGGGACTCAAAGAGGTCATCAACGATCGGTACGAT 508 CCTGTTGCAGGCTGCTGATATTGAGCATATCGTACCGATCGTTGATGACC 509 ATATCAGCAGCCTGCAACAGGACGGCAAAACTTTCATCGACTTCAAGAAA 5010 CAGAGGGAGCTTGTCGTTGTATTTCTTGAAGTCGATGAAAGTTTTGCC 4811 TACAACGACAAGCTCCCTCTGTACATTAGCAATCCCAACTACAAGGTGAA 5012 GTTCTCCTTTGTGACGGCATAGACGTTCACCTTGTAGTTGGGATTGCTAA 5013 TCTATGCCGTCACAAAGGAGAACACCATCATTAACCCAAGCGAGAACGGG 5014 GAGGATCCGTTTGATCCCATTTGTGGAAGTGTCCCCGTTCTCGCTTGGGT 5015 ACAAATGGGATCAAACGGATCCTCATCTTTTCCAAAAAGGGGTACGAGAT 5016 GTACgtcgacCCCAATCTCGTACCCCTTTTTGGAAAAGA 291.½«¸÷ÌõÒýÎïÖØÐüΪ100M¡£2.ÖÆ±¸10XµÄÒýÎï»ìºÏÎォÿÌõÒýÎï¸÷È¡11»ìºÏÔÚÒ»Æð£¬È»ºó¼ÓMilli-QË®ÖÁ ÖÕÌå»ý200 ¦Ì 1¡£3.ÖÆ±¸50 ¦Ì 1µÄPCR·´Ó¦Ìåϵa. 8 ¦Ì 1 10¦¶µÄÒýÎï»ìºÏÎï+5 ¦Ì 1 10¦¶ PCR»º³åÒºb. 1 ¦Ì 1 dNTP µ×Îï(2. 5mM each)c. 1 ¦Ì 1 pyrobest ¦£¡À|8| (Takara)d. 35 ¦Ì 1 Milli-Q Ë®4¡¤ PCR·´Ó¦Ìõ¼þ
a. 95 ¡ãC 2minb. 95¡ãC 20secc. 52 ¡ãC Imind. 72 ¡ãC 2mine.ÖØ¸´²½Öèb_d29´Îf. 72 ¡ãC IOmin5.È¡1 ¦Ì 1 PCR²úÎï(²»ÐèÒª´¿»¯)×÷Ϊģ°åÓÃÓÚµÚ¶þ´ÎPCRa. 1 ¦Ì 1 of PCR ²úÎïb. 5 ¦Ì 1 IOX PCR »º³åÒºc. 1 ¦Ì 1 dNTP µ×Îï(2. 5mM each)d. 0¡¤ 5¦Ì 1 1 ºÅÒýÎï(¦©¦¯¦¯¦Ì¦¬)e. 0. 5¦Ì 1 16 ºÅÒýÎï(¦©¦¯¦¯¦Ì¦¬)f. 1 ¦Ì 1 pyrobest À©Ôöø(Takara)g. 41 ¦Ì 1 Milli-Q Ë®h.ÖØ¸´²½Öè6µÄPCR·´Ó¦ÓÃBgl II-Sal IøÇн«À©Ôö²úÎï²¢Ñǿˡµ½pUHDlO-3-displayÔØÌåÖУ¬ÖØ×éÖÊ Á£½øÐвâÐòÑéÖ¤£¬½á¹ûÔÚpUHDlO-3-displayµÄBgl IIºÍSal IøÇÐλµã¼ä²åÈëÁË SEQ ID NO 5ËùʾDNA£¬±íÃ÷¹¹½¨µÄÖØ×éÖÊÁ£ÕýÈ·£¬¼Ç×÷pUHD10-3-display-PAD4¡£ÍêÈ«ÅàÑø»ùº¬10%СţѪÇå(Hyclone)ºÍ100U/mlË«¿¹(ÇàÁ´Ã¹ËØ£¬Sigma)µÄ DMEMÅàÑø»ù(Invitrogen)£¬ÓÃÓÚÅàÑøHI2"ϸ°û¡£ÔÚתȾ24Сʱǰ½ÓÖÖH1299ϸ°ûʹÆäÔÚתȾʱ´ïµ½60% _80%Âú¶È£¬È¥³ýÍêÈ«Åà Ñø»ù£¬ÓÃLipofectamine 2000 (Invitrogen)½«pTet-on (±àÂërtTAת¼Òò×Ó£¬¿ÉÓÚËÄ»·ËØ ÏìÓ¦Æô¶¯×ÓÅä¶Ô¶Ô»ùÒò½øÐÐTet onµ÷¿Ø)(Clontech)ºÍÄ¿µÄÖÊÁ£pUHD10-3-display-PAD4 ÔÚÎÞѪÇåÅàÑø»ùÖлìºÏ²¢¼ÓÈëϸ°ûÅàÑøÅÌÖУ¬·õÓý4-6Сʱºó£¬»»³ÉÍêÈ«ÅàÑø»ù¼ÌÐø ÅàÑø£¬×ªÈ¾24Сʱºó£¬½«Ï¸°û°´1 5µÄ±ÈÀý½ÓÖÖÓÚеÄÅàÑøÃóÖУ¬²¢¼ÓÈë450yg/ml G418 (Amersco)ɸѡ¿¹ÐÔϸ°û¡£É¸Ñ¡Á½Öܺ󣬽«G418¿¹ÐÔϸ°û°´5 X IO5ϸ°û/IOcmƽÃóµÄ ÃܶȽÓÖÖ£¬²¢¼ÓÈë2¦Ì g/ml d0XyCyCline(D0X£¬Ò»ÖÖËÄ»·ËصÄÑÜÉúÎ¾ßÓиüÇ¿µÄÓÕµ¼Ð§¹û ºÍÎȶ¨ÐÔ)(Sigma)ÓÕµ¼PAD4±í´ï¡£ÓÕµ¼48Сʱºó£¬ÊÕ¼¯Ï¸°û¡£Ï¸°û¼ø¶¨ÓÃ1 400Ï¡Ê͵Ŀ¹c-myc±êÇ©µÄµ¥¿¹(9E10£¬Calbiochem)4¶È±ê ¼Çϸ°û±íÃæµÄPAD4-c-mycµ°°×¡£·õÓý30minºó£¬ÔÙÓÃ1 300Ï¡Ê͵ÄÍÿ¹ÊóµÄFITC±ê ¼ÇµÄ¶þ¿¹(Jackson ImmunoResearch) 4¶È·õÓý30min¡£±»±ê¼ÇµÄϸ°ûÖØÐüÓÚDMEMÅàÑø»ù (Invitrogen,CA)ÖС£ÑùÆ·ÔÚBD FACS Aria II (Becton Dickinson)ÉϽøÐÐÎÞ¾ú·ÖÑ¡£¬½«Ô¼ 5%¾ßÓÐ×îÇ¿FITCÓ«¹âµÄϸ°û·ÖÑ¡³öÀ´¡£¾¹ýÈýÂÖ·ÖÑ¡£¬»ñµÃÁË 63%µÄϸ°û±íÃæÕ¹Ê¾PAD4 µÄϸ°û£¬¼Ç×÷H1299-tet on PAD4ϸ°û¡£DoxÓÕµ¼Ç°ºóµÄH1299_tet on-PAD4ϸ°ûÈçͼ1Ëùʾ¡£Í¼1ÖУ¬(A)Ó«¹âÏÔ΢¾µ¹Û ²ìPAD4ÔÚH1299ϸ°û±íÃæµÄ±í´ï¡£¿¹c_myc±êÇ©¿¹Ìå±ê¼ÇH1299_tet on_PAD4ϸ°ûÔÚÓÐ ÎÞDoxʱ±íÃæPAD4µÄ±í´ïˮƽ¡£(B)Á÷ʽϸ°ûÒǼì²âH1299-tet on_PAD4ϸ°ûÔÚÓÐÎÞDox ʱ±íÃæPAD4µÄ±í´ïˮƽ¡£±íÃ÷£¬ÔÚϸ°ûά³ÖµÄ¹ý³ÌÖУ¬ÓÉÓÚûÓÐDox£¬Ï¸°û²»»á±í´ïPAD4¿¹ Ô£¬ÓÐÀûÓÚϸ°ûµÄÀ©Ôö¡£Ö»Óе±ÔÚÅàÑø»ùÖмÓÈëDoxʱ£¬H1299ϸ°û²ÅÄÜÔÚ¶Ìʱ¼äÄÚÔÚϸ°û±íÃæ±í´ïPAD4¿¹Ô¡£¶þ¡¢½«´ýɸѡ¿¹ÌåչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæÏ¸¾ú±í´ïÔØÌå pBAD30-KmR-GFPmut2¡¢pAK200-26_10 (anti-Digoxigenin scFv) ºÌ¿Ú pAK200-M18 ÔÚÎÄÏ×(Jung ST, Jeong KJ, Iverson BL, Georgiou G=Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. Biotechnol Bioeng 2007,98(1) 39-47.)Öй«¿ª¹ý¡£pAK200-M18Öк¬ÓÐPAD4µÄ¿¹Ìå(¼´M18)µÄ±àÂë»ùÒò£¬¸Ã»ùÒòÐòÁÐÈçSEQ ID NO 1Ëùʾ¡£M18¿¹ÌåµÄ°±»ùËáÐòÁÐÈçSEQ ID N0:2Ëùʾ¡£pAK200-26-10Öк¬ÓÐÒõÐÔ¶ÔÕÕ¿¹Ìå26_10 (¿¹µØ¸ßÐÁ±êÇ©(DIG)µÄ¿¹Ìå)µÄ±àÂë »ùÒò£¬¸Ã»ùÒòÐòÁÐÈçSEQ ID N0:3Ëùʾ¡£¶ÔÕÕ¿¹Ìå26-10µÄ°±»ùËáÐòÁÐÈçSEQ ID NO :4Ëù
7J\ ¦ÏpBAD30-KmRÔØÌåÊÇÒ»¸öaraBADÆô¶¯×ÓÑϸñµ÷¿Øµ°°×±í´ïµÄÔØÌå¡£Ïòϸ¾úÖе¼ÈëpBAD30-KmR-GFPmut2µÄÄ¿µÄÊÇʹϸ¾úÔÉúÖÊÌå·¢Ó«¹â£¬±ãÓÚɸѡ¡£pAK200ÔØÌåÊÇÒ»ÖÖÊɾúÌåչʾµÄÔØÌ壬Ëü½«ÍâÔ´µ°°×µÄC¶ËÓëM13ÊɾúÌåµÄgp3 µ°°×ÐγÉÈںϵ°°×£¬Í¨¹ýgp3궨ÔÚϸ¾úÄÚĤÍâ²à´Ó¶ø½«ÍâÔ´µ°°×չʾÔÚϸ¾úÖÜÖʿռ䡣 ½«Ï¸¾úÍâ±ÚÈ¥³ýºó½«Äܽ«Ä¿µÄµ°°×չʾÔÚϸ¾ú±íÃæ¡£E. coli Jude-I ÔÚÎÄÏ×(F£¬[TnlO (Tetr) proAB+lacIq ¦¤ (lacZ)M15]mcrA ¦¤ (mrr-hsdRMS-mcrBC) ¦µ80(11¦Â¦Ï¦¦¦¤¦¬15 ¦¤ lacX74 deoR recAl araD139A (ara leu) 7697 galU galK rpsL endAl nupG)(Jung ST,Jeong KJ,Iverson BL,Georgiou G :Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. Biotechnol Bioeng 2007,98(1) 39-47.)Öй«¿ª¹ý¡£E coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°ûµÄÖÆ±¸A.ÌôÈ¡µ¥¿Ë¡½ÓÖÖÓÚ5ml SOBÅàÑø»ùÖÐ37¶È£¬250rpmÅàÑø16Сʱ£»B.½«5ml¹ýÒ¹ÅàÑøÒº½ÓÖÖÓÚ500ml SOBÅàÑø»ùÖУ¬37¶È£¬250rpmÅàÑøÖÁ0D600µ½ 1. O £»C.½«ÅàÑøÒºÖÃÓÚ±ùÉÏ30·ÖÖÓ£¬È»ºó4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓÊÕ¼¯Ï¸¾ú£»D.ÆúÉÏÇ壬ÓÃ500ml±ùÉÏÔ¤ÀäµÄÎÞ¾ú³¬´¿Ë®ÖØÐü¾úÌåE. 4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓ£¬ÆúÉÏÇ壬ÓÃ250ml±ùÉÏÔ¤ÀäµÄÎÞ¾ú³¬´¿Ë®ÖØÐü¾úÌåF. 4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓ£¬ÆúÉÏÇ壬ÓÃ50ml±ùÉÏÔ¤ÀäµÄÎÞ¾ú³¬´¿Ë®ÖØÐü¾úÌåG. 4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓ£¬ÆúÉÏÇ壬ÓÃ1. 5ml±ùÉÏÔ¤ÀäµÄ10% (¦Í/¦Í)¸ÊÓ͵ÄÎÞ¾ú ³¬´¿Ë®ÈÜÒºÖØÐü¾úÌ壬50 ¦Ì 1/¹Ü·Ö×°¸ÐÊÜ̬ϸ°û£¬ÂíÉÏÖÃÓÚ-70¶È³¬µÍαùÏä±£´æ¡£µçת»¯E coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°ûA.½«0. IcmµÄµç»÷±ÖÃÓÚ±ùÉÏÔ¤À䣬ͬʱ´Ó_70¶È³¬µÍαùÏäÈ¡³öÒ»¹ÜE coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬ÖÃÓÚ±ùÉÏÈÚ»¯¡£B.½«ÖÊÁ£ÈÜÒº(1-2 ¦Ì 1)¼ÓÈëÒÑÈÜ»¯µÄE coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°ûÖУ¬Ñ¸ËÙ ²¢Îºͻì„ò¡£C.ÂíÉϽ«¸ÐÊÜ̬-ÖÊÁ£»ìºÏÎï×ªÒÆµ½0. IcmµÄµç»÷±ÖУ¬½«µç»÷±ÖÃÓÚGene
12Pulser II (Bio-Rad)µç´©¿×ÒÇÉÏ£¬ÒÔ1. 8kv£¬25 ¦Ì F£¬200 ¦¸µÄµç»÷Ìõ¼þ½øÐеç»÷¡£µç»÷³£ Êý¿É¿ØÖƵ½4-5ºÁÃë¡£D.ѸËÙ¼ÓÈëIml SOCÅàÑø»ù(³£ÎÂ)ÖØÐüµç»÷ºóµÄϸ¾ú£¬²¢×ªÒƵ½Ò»¸ö15mlÀëÐÄ ¹ÜÖУ¬ÖÃÓÚ37¶ÈÒ¡´²£¬220rpmÅàÑø1¸öСʱ¡£E.½«¸´ËÕºóµÄ¾úÒºÒÔ300 ¦Ì l/10cmƽÃóÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØºÍ¿¨ÄÇÃ¹ËØµÄLB¹ÌÌå Ñ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£°´ÕÕÈçÉÏ·½·¨½«pBAD30-KmR-GFPmut2ºÍpAK200-26-10¹²Í¬×ªÈëE.coli Jude-I£¬ µÃµ½º¬ÓÐ pBAD30-KmR-GFPmut2 ºÍ pAK200-26_10 µÄ E. coli Jude-I¡£°´ÕÕÈçÉÏ·½·¨½«pBAD30-KmR-GFPmut2ºÍpAK200-M18¹²Í¬×ªÈëE.coli Jude-I£¬µÃ µ½º¬ÓÐ pBAD30-KmR-GFPmut2 ºÍ pAK200_M18 µÄ E. coli Jude-I¡£½«º¬ÓÐpBAD30-KmR-GFPmut2 ºÍ pAK200-26_10 µÄ E.coli Jude-I »òº¬ÓÐ pBAD30-KmR-GFPmut2 ºÍ pAK200_M18 µÄ E. coli Jude-I ÔÚÌí¼ÓÁË 20mg/ml ÆÏÌÑÌÇ£¬40 ¦Ì g/ mlÂÈÃ¹ËØ(Sigma)ºÍ50 ¦Ì g/ml¿¨ÄÇÃ¹ËØ(Sigma)µÄTB (Terrific Broth)ÅàÑø»ùÖÐÅàÑø 37¶È¹ýÒ¹¡£½«¹ýÒ¹ÅàÑøÒº°´1 100µÄ±ÈÀý½ÓÖÖµ½ÐÂÏʵÄTBÅàÑø»ùÖÐ(²»º¬ÆÏÌÑÌÇ)£¬37 ¶ÈÅàÑøÖÁ OD6tltl µÈÓÚ 0. 5¡£È»ºó¼ÓÈë ImM IPTG(Sigma)ºÍ 2mg/ml L-arabinose (Sigma)ÖÁÓÚ 16¶ÈÓÕµ¼¿¹ÌåºÍÂÌɫӫ¹âµ°°×µÄ±í´ï¡£ÖƱ¸Ï¸¾úÔÉúÖÊÌåÓÕµ¼18Сʱºó£¬ÀëÐÄÊÕ¼¯¾úÌå(¾úÌåŨ¶ÈΪIml¾úÌåµÄ OD6tltl ֵΪ 4. 5)£¬Óà Iml IOmM Tris-HCl(pH 8. 0)Ï´Á½´Î£¬ÔÙÖØÐüÓÚ Iml STE ÈÜÒºÖÐ(0. 5M Sucrose, IOmM Tris-HCl, IOmM EDTA£¬pH 8¡¤ 0)£¬ÖÃÓÚ 37 ¶È·õÓý 30min¡£12£¬000g ÀëÐÄÊÕ¼¯Ï¸ ¾ú£¬È»ºóÓÃÈÜÒº A (0. 5M Sucrose, 20mM MgCl2, IOmM M0PS£¬pH 6.8)Ï´Ò»´Î£¬ÔÙÖØÐüÓÚ Iml º¬ ÓÐlmg/mlÈܾúøµÄÈÜÒºAÖУ¬37¶È·õÓý15min¡£×îºó12£¬OOOgÀëÐÄÊÕ¼¯Ï¸¾úÔÉúÖÊÌ壬²¢ ÖØÐüÓÚº¬ÓÐBSAºÍÍÑÖ¬ÄÌ·Û¡¢pH6. 5µÄoptimal-MEMÅàÑø»ùÖУ¬ÖÁϸ¾úÔÉúÖÊÌåµÄ Ũ¶ÈΪImlÐüÒºµÄ0D_ֵΪ10£¬»ñµÃϸ¾úÔÉúÖÊÌåÐüÒº¡£Èý¡¢¿¹Ìåɸѡ·½·¨µÄÃþË÷Doxycycline ¹º×Ô Sigma£¬²úƷĿ¼ºÅΪ D9891¡£optimal-MEM ÅàÑø»ù¹º×Ô Invitrogen£¬²úƷĿ¼ºÅΪ31985¡£(Ò» )Ñé֤ƽ°åÌÔÑ¡·¨(panning)ÄÜ·ñÓÃÓÚ¿¹ÌåɸѡʵÑé×é·½·¨(A)½«H1299-tet on_PAD4ϸ°û°´5X IO5ϸ°û/IOcmƽÃó½ÓÖÖ£¬²¢¼Ó Èë2¦Ì¦Â/¦Ð¦É1 doxycyclineÓÕµ¼PAD4±í´ï¡£ÓÕµ¼60Сʱºó£¬Æ½ÃóÓÃPBSÏ´Ò»±é£¬È»ºó¼ÓÈ뺬 ÓÐBSAºÍÍÑÖ¬ÄÌ·ÛµÄoptimal-MEM pH6. 5ÅàÑø»ù³£Î·â±Õ20min¡£½«IOmlϸ¾úÔ ÉúÖÊÌåÐüÒº(10mlϸ¾úÔÉúÖÊÌåÐüÒºµÄOD6tltlֵΪ80)¼ÓÈ뵽ÿ¸öƽÃóÖУ¬·ÅÖÃÓÚ37¶È¡¢pH Öµ6. 5¡¢Ë®Æ½Ò¡´²ÖÐÒÔ50ת/·ÖÖÓ·õÓý1Сʱ¡£·õÓý½áÊø£¬ÓÃPBSÏ´Èý´Î£¬È¥³ýδ½áºÏµÄϸ ¾úÔÉúÖÊÌ塣ʵÑéÖе¥¶À¼ÓչʾM18µÄϸ¾úÔÉúÖÊÌå»òչʾ26-10µÄϸ¾úÔÉúÖÊÌå¡£ÓÉÓÚϸ¾úÔÉúÖÊÌå´øÓÐGFPÓ«¹â£¬Ö±½ÓÔÚÓ«¹âÏÔ΢¾µÏ¹۲ìϸ¾úÔÉúÖÊÌåÓëϸ°û µÄ½áºÏ¡£½á¹ûÈçͼ2Ëùʾ¡£Í¼2AΪչʾM18µÄϸ¾úÔÉúÖÊÌåÓëH1299-tet on-PAD4·õÓý£» ͼ2BΪչʾ26-10ϸ¾úÔÉúÖÊÌåÓëH1299-tet on_PAD4·õÓý£»Í¼2CΪչʾM18ϸ¾úÔÉú ÖÊÌåÓëH1299ϸ°û·õÓý£»Í¼2DΪչʾ26-10ϸ¾úÔÉúÖÊÌåÓëH1299ϸ°û·õÓý¡£Í¼2AÏÔʾ ÎªÌØÒì½áºÏʵÑ飬¶øÍ¼2B¡¢CºÍDΪ¶ÔÕÕʵÑ顣ʵÑéÉè3´ÎÖØ¸´£¬½á¹ûÒ»Ö¡£½á¹û±íÃ÷£¬Ö»ÓРչʾÁË¿¹PAD4µÄµ¥Á´¿¹ÌåµÄϸ¾úÔÉúÖÊÌåÄܽáºÏµ½H1299-tet on_PAD4ϸ°ûµÄ±íÃæ£¬¶øÕ¹Ê¾¿¹DIG±êÇ©µÄϸ¾úÔÉúÖÊÌå²»ÄÜÓëH1299-tet0n-PAD4ϸ°û½áºÏ¡£Á½ÖÖϸ¾úÔÉúÖÊÌåϸ °û¾ù²»ÄÜºÍÆÕͨµÄH1299ϸ°û½áºÏ¡£Ö¤ÊµM18-ϸ¾úÔÉúÖÊÌåÄܽáºÏµ½Ìù±ÚµÄH1299-PAD4 ϸ°û±íÃæ¡£ÇÒ¶ÔÕÕ¿¹ÌåµÄ·ÇÌØÒì½áºÏˮƽ·Ç³£µÍ¡£Ö¤Ã÷ƽ°åÌÔÑ¡·¨¿ÉÒÔÓÃÓÚɸѡ¿¹Ìå¡£(¶þ)ÑéÖ¤Á÷ʽ·ÖÑ¡ÄÜ·ñÓÃÓÚ¿¹ÌåɸѡÊÕ¼¯ÓÕµ¼¹ýµÄH1299-tet on_PAD4ϸ°û£¬ÖØÐüÓÚº¬ÓÐIOmM EDTAºÍ1 % BSA optimal-MEM pH6. 5 ÅàÑø»ùÖС£½« IO6 H1299_tet on_PAD4 ϸ°ûÓë Iml 0D_ ֵΪ 2 µÄչʾ M18µÄϸ¾úÔÉúÖÊÌå»òչʾ26-10µÄϸ¾úÔÉúÖÊÌåÐüÒº(ImlÐüÒºµÄOD6tltlֵΪ2)»ìºÏ£¬Öà ÓÚ¾²Òô»ìºÍÆ÷ÉÏÓÚ37¶È¡¢pH6. 5µÄÌõ¼þÏ·õÓý1Сʱ¡£·õÓýÍêºó£¬300gÀëÐÄ2·ÖÖÓÒÔ³ýÈ¥ δ½áºÏµÄϸ¾úÔÉúÖÊÌå¡£ÑùÆ·ÖØÐüÓÚDMEMÅàÑø»ùÖУ¬ÓÃÁ÷ʽϸ°ûÒÇBD FACS Calibur flow cytometer (Becton Dickinson)½øÐзÖÎö¡£Í¼3AΪϸ¾úÔÉúÖÊÌåºÍH1299ϸ°ûͨ¹ý¿¹ÌåM18 ºÍ¿¹ÔPAD4½áºÏÔÚÒ»ÆðµÄʾÒâͼ¡£H1299-tet on-PAD4ϸ°ûÃ÷ÏÔ±Èϸ¾úÔÉúÖÊÌå´ó£¬ÔÚÁ÷ ʽϸ°ûÒÇÉϱíÏÖ³ö¸üÇ¿µÄǰÏòÉ¢Éä¹âºÍ²àÏòÉ¢Éä¹âÐźţ¬Í¨¹ýÉ¢Éä¹âÐźſÉÒÔ½«Ï¸°ûºÍ²Ð ÁôµÄϸ¾úÔÉúÖÊÌåÇø·Ö¿ªÀ´(ͼ3B)¡£Í¼3BÖÐRlÇøÓòΪH1299-tet on_PAD4ϸ°û¼°Ä¿µÄ¸´ ºÏÎï¡£½«¸ÃRlÇøÓòÄÚµÄϸ°ûºÍϸ°û_ϸ¾úÔÉúÖÊÌå¿ÉÒÔͼʾΪͼ3C¡£H1299-tet on-PAD4 ϸ°û½áºÏչʾM18ϸ¾úÔÉúÖÊÌ壬¶ø²»½áºÏÓÃÓÚÒõÐÔ¶ÔÕÕµÄչʾ26-10ϸ¾úÔÉúÖÊÌå¡£Á½ ÖÖϸ¾úÔÉúÖÊÌå¾ù±í´ïÂÌɫӫ¹âµ°°×GFPmut2£¬Òò´Ë±»488nm¼¤¹â¼¤·¢ºó·¢ÂÌɫӫ¹â¡£ÓÉ Í¼3C¿É¼û£¬ÒòչʾM18ϸ¾úÔÉúÖÊÌåÄÜÌØÒì½áºÏH1299-tet on-PAD4ϸ°û¿É¼ì²âµ½Ã÷ÏÔ µÄ530/30nm²¨³¤µÄÓ«¹âÐźţ»¶øÕ¹Ê¾26-10ϸ¾úÔÉúÖÊÌ弸ºõ²»½áºÏH1299_tet on-PAD4 ϸ°û£¬Ö»Äܼì²âµ½·Ç³£µÍˮƽµÄ±³¾°Ó«¹â¡£ÑùÆ·¿ÉÓÃÁ÷ʽ·ÖÑ¡ÒÇFACSAria II (Becton Dickinson£¬Ò²¿ÉÓñðµÄÁ÷ʽ·ÖÑ¡ÒÇ)¸ù¾ÝÓ«¹âÐźŷÖÑ¡H1299_tet on-PAD4ϸ°ûÓëÕ¹ ʾM18¿¹ÌåµÄϸ¾úÔÉúÖÊÌåµÄ¸´ºÏÎͼ3CÖÐSÇøÓòΪ·ÖÑ¡Çø¡£½á¹ûɸѡµ½H1299-tet on-PAD4ϸ°ûÓëչʾM18¿¹ÌåµÄϸ¾úÔÉúÖÊÌåµÄ¸´ºÏÎ±íÃ÷Á÷ʽ·ÖÑ¡·¨Ò²¿ÉÓÃÓÚ¿¹Ìåɸ Ñ¡¡£(Èý)·õÓýÌõ¼þµÄÓÅ»¯½«ÓÕµ¼¹ýµÄH1299-tet on_PAD4ϸ°ûÊÕ¼¯²¢ÖØÐüÓÚº¬ÓÐIOmM EDTAºÍ1 % BSA¡¢pH ²»Í¬µÄoptimal-MEMÅàÑø»ùÖС£½«IO6ϸ°ûÓëImlչʾM18ϸ¾úÔÉúÖÊÌåÐüÒº(ImlÐüÒºµÄ 0D_ֵΪ2)»ìºÏ£¬ÖÃÓÚ¾²Òô»ìºÍÆ÷ÉÏÓÚ37¶È¡¢pH²»Í¬µÄÌõ¼þÏ·õÓý1Сʱ¡£pHÖµ·Ö±ðΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0£¬7. 3 »ò 7. 5¡£·õÓýÍê³ÉµÄÑùÆ·ÔÚÁ÷ʽ·ÖÑ¡ÒÇFACSAria II (Becton Dickinson)Éϼì²âϸ¾úÔÉú
ÖÊÌå½áºÏÐźš£Í¬Ê±ÒÔչʾ26-10¿¹ÌåµÄϸ¾úÔÉúÖÊÌå×÷Ϊ¶ÔÕÕ¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûȡƽ¾ùÊý¡£Í¼4Ϊչʾ¿¹PAD4¿¹ÌåM18ϸ¾úÔÉúÖÊÌå»òÒõ ÐÔ¶ÔÕÕչʾ26-10¿¹Ìåϸ¾úÔÉúÖÊÌåÔÚ²»Í¬µÄpHÖµÌõ¼þÏÂÓëÐü¸¡µÄH1299-tet on-PAD4 ϸ°û½áºÏÊýÄ¿¡£ÔÚpHΪ5. 5µ½7. 0Ö®¼ä£¬Õ¹Ê¾M18µÄϸ¾úÔÉúÖÊÌåÓëH1299_tet on_PAD4 ϸ°ûµÄ½áºÏÊý(ÔÚÁ÷ʽÖÐÒÔGFPÓ«¹âÇ¿¶È±íʾ)Ã÷ÏÔ¸ßÓÚ´ËpHÖµ·¶Î§Ö®ÍâչʾM18µÄϸ ¾úÔÉúÖÊÌåÓëH1299-tet on-PAD4ϸ°ûµÄ½áºÏÊý¡£¶øÔÚpHΪ5. 5µ½7. 0Ö®¼äºÍÖ®Í⣬չʾ ÒõÐÔ¶ÔÕÕ¿¹Ìå26-10µÄϸ¾úÔÉúÖÊÌåÓëH1299-tet on-PAD4ϸ°ûµÄ½áºÏÊý¶¼´¦ÓÚµÍˮƽ״ ̬¡£ÀýÈçÕ¹Ê¾ÌØÒ쿹ÌåM18µÄϸ¾úÔÉúÖÊÌåÓëH1299-tet on_PAD4ϸ°û·õÓýºó£¬µ±pHֵΪ 5. 0ʱ£¬½áºÏÐźÅ(Ó«¹âÇ¿¶È)Ϊ662 £»µ±pHֵΪ5. 5ʱ£¬½áºÏÐźÅΪ1136 £»µ±pHֵΪ6. 0ʱ£¬½áºÏÐźÅΪ2857 £»µ±pHֵΪ6. 5ʱ£¬½áºÏÐźÅΪ2711 £»µ±pHֵΪ7. 0ʱ£¬½áºÏÐźÅΪ 839 £»µ±pHֵΪ7. 5ʱ£¬½áºÏÐźÅΪ439¡£ÒÔÉÏʵÑé˵Ã÷pHÔÚ5. 5µ½7. 0Ö®¼äÓÐÀûÓÚ¶ÔÕ¹ Ê¾ÌØÒ쿹ÌåM18µÄϸ¾úÔÉúÖÊÌåµÄ¸»¼¯¡£µ±pHÖµ´¦ÓÚÉúÀíÌõ¼þpH7. 5ʱ£¬ÌØÒì½áºÏÐźŷdz£µÍ¡£¶øpHÖµ½µµ½ÈõËáÐÔʱ£¬½á ºÏÐźÅÓÐÃ÷ÏÔÌá¸ß¡£ÕâºÜ¿ÉÄÜÊÇÒòΪÔÚÉúÀíÌõ¼þϲ¸È鶯Îïϸ°ûºÍϸ¾ú±íÃæ¶¼´øÓиºµç ºÉ£¬½µµÍPH¿ÉÒÔÖкͲ¿·Ö¸ºµçºÉ£¬½µµÍÁ½ÕßÖ®¼äµÄ¾²µçÅų⣬´Ó¶øÓÐÀûÓÚ¿¹Ô-¿¹ÌåµÄ½á ºÏ¡£µ«PHÖµ¹ýµÍ£¬½áºÏÐźÅÒ²»á¿ªÊ¼Ï½µ¡£Õâ¿ÉÄÜÊÇÓÉÓÚPAD4µ°°×½âÕÛµþÔì³É¿¹Ô±íλ ±ä»¯µÄÔÒò¡£×ۺϿ¼ÂǽáºÏÐźż°µ°°×½á¹¹Îȶ¨ÐÔµÄË«ÖØÒòËØ£¬Ñ¡¶¨ÔÚPH6. 5×÷Ϊ×îÓÅÌõ ¼þ¡£ËÄ¡¢¿¹Ìåɸѡ( Ò» )ƽ°åÌÔÑ¡·¨(panning)½«Õ¹Ê¾26-10¿¹ÌåµÄϸ¾úÔÉúÖÊÌåµÄÐü¸¡ÒºÓëչʾM18µÄϸ¾úÔÉúÖÊÌåµÄÐü¸¡Òº »ìºÏ£¬µÃµ½»ìºÏÐü¸¡Òº£¬Ê¹»ìºÏÐü¸¡ÒºÖÐչʾM18µÄϸ¾úÔÉúÖÊÌåÓëչʾ26-10¿¹ÌåµÄϸ¾ú ÔÉúÖÊÌåµÄÊýÄ¿±ÈΪ1 1000»ò5 100£¬È»ºó½«»ìºÏÐü¸¡Òº·Ö±ðÓÃÆ½°åÌÔÑ¡·¨½øÐÐɸѡ ¿¹Ìå¡£½«H1299_tet on_PAD4ϸ°û°´5 X IO5ϸ°û/IOcmƽÃó½ÓÖÖ£¬ÔÚÍêÈ«ÅàÑø»ùÖмÓÈë 2 ¦Ì g/ml doxycycline£¬ÓÕµ¼PAD4±í´ï¡£ÓÕµ¼60Сʱºó£¬Æ½ÃóÓÃPBSÏ´Ò»±é£¬È»ºó¼ÓÈ뺬ÓÐ 1% BSAºÍÍÑÖ¬ÄÌ·ÛµÄoptimal-MEM pH6. 5ÅàÑø»ù³£Î·â±Õ20min¡£½«IOml»ìºÏÐü¸¡ Òº(IOml»ìºÏÐü¸¡ÒºµÄOD6tltlֵΪ80)¼ÓÈ뵽ÿ¸öƽÃóÖУ¬·ÅÖÃÓÚ37¶È¡¢pHÖµ6. 5¡¢Ë®Æ½Ò¡ ´²ÖÐÒÔ50ת/·ÖÖÓ·õÓý1Сʱ¡£·õÓý½áÊø£¬ÓÃPBSÏ´Èý´Î£¬È¥³ýδ½áºÏµÄϸ¾úÔÉúÖÊÌ壬±£ ÁôÊ£Óà²úÎï¡£»ñµÃ¿¹ÌåÐòÁн«Ê£Óà²úÎïÓÃÒÈøø½â£¬´ÓÖлØÊÕ±í´ï¿¹ÌåµÄÖÊÁ££¬½«»ØÊյıí´ï ¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄ LB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£´ÓÑôÐÔת»¯×ÓÖÐÌáÈ¡ÖÊÁ££¬½øÐвâÐò£¬µÃµ½Ä¿µÄ¿¹ÌåµÄ±à Âë»ùÒòÐòÁУ¬ÐòÁÐÈçSEQ ID NO :1Ëùʾ£¬»ùÒòÐòÁÐÕýÈ·£¬ËµÃ÷±¾·¢Ã÷·½·¨Äܹ»É¸Ñ¡µÃµ½ÕýÈ· µÄ¿¹Ìå¡£ÔÙͨ¹ý»ùÒò¹¤³Ì±í´ïºÍ´¿»¯µÃµ½Ä¿µÄ¿¹Ì塣ͳ¼Æ¸»¼¯Ð§Âʽ«Ê£Óà²úÎïÓÃÒÈøø½â£¬´ÓÖлØÊÕ±í´ï¿¹ÌåµÄÖÊÁ££¬½«»ØÊյıí´ï ¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄ LB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Ëæ»úÌôÈ¡48¸öת»¯×Ó£¬²ÉÓþúÂäPCR¼ø¶¨¸»¼¯ºóµÄM18 ´¿¶È£¬ÔÙͳ¼Æ¸»¼¯Ð§ÂÊ¡£¸»¼¯Ð§ÂʵļÆË㹫ʽ¸»¼¯ºóµÄM18´¿¶È/¸»¼¯Ç°µÄM18´¿¶È¡£¼ø¶¨ÒýÎïÐòÁÐ(M18ÌØÒìÒýÎï)ÈçÏÂ5¡¯ -ATATGCTAGCGATATTCAGATGACACAGACT-3¡¯ £»5 ¡¯ -GCGTTTGCCATCTTTTCATAATCAAAATCACC-3¡¯¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûȡƽ¾ùÊý¡£½á¹ûÈçͼ5Ëùʾ¡£µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔÉúÖÊÌåµÄ´¿¶ÈΪ 0. 1 %ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ6. 4%£¬ÌÔÑ¡±íÏÖ³öºÃµÄ¸»¼¯Ð§ÂÊ£¬Îª64±¶¡£µ±ÓÃÓÚʵÑéµÄ»ì ºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔÉúÖÊÌåµÄ´¿¶ÈΪ5%ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ25%£¬ÌÔÑ¡µÄ¸»¼¯ ЧÂÊΪ5±¶¡£µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£
µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£(¶þ)Á÷ʽ·ÖÑ¡·¨½«Õ¹Ê¾26-10¿¹ÌåµÄϸ¾úÔÉúÖÊÌåµÄÐü¸¡ÒºÓëչʾM18µÄϸ¾úÔÉúÖÊÌåµÄÐü¸¡Òº »ìºÏ£¬µÃµ½»ìºÏÐü¸¡Òº£¬Ê¹»ìºÏÐü¸¡ÒºÖÐչʾM18µÄϸ¾úÔÉúÖÊÌåÓëչʾ26-10¿¹ÌåµÄϸ¾ú ÔÉúÖÊÌåµÄÊýÄ¿±ÈΪ1 1000»ò5 100£¬È»ºó½«»ìºÏÐü¸¡Òº·Ö±ðÓÃÁ÷ʽ·ÖÑ¡·¨½øÐÐɸѡ ¿¹Ìå¡£½«H1299-tet on_PAD4ϸ°û°´5 X IO5ϸ°û/IOcmƽÃó½ÓÖÖ£¬ÔÚÍêÈ«ÅàÑø»ùÖмÓÈë 2 ¦Ì g/ml doxycycline£¬ÓÕµ¼PAD4±í´ï¡£ÓÕµ¼60Сʱºó£¬Æ½ÃóÓÃPBSÏ´Ò»±é£¬Ã¸½âÊÕ¼¯ÓÕµ¼ ¹ýµÄ H1299-tet on_PAD4 ϸ°û£¬²¢ÖØÐüÓÚº¬ÓÐ IOmM EDTA ºÍ 1 % BSA¡¢pH6. 5 µÄ optimal-MEM ÅàÑø»ùÖС£½«IO6CellsÓëIml»ìºÏÐü¸¡Òº(Iml»ìºÏÐü¸¡ÒºµÄOD6tltlֵΪ2)»ìºÏÓÚ1. 5ml ÀëÐĹÜÖУ¬ÖÃÓÚ¾²Òô»ìºÍÆ÷ÉÏÓÚ37¶È¡¢pH6. 5µÄÌõ¼þÏ·õÓý1Сʱ¡£È¥³ý·õÓýÌåϵÖÐδ½áºÏµÄϸ¾úÔÉúÖÊÌ彫·õÓý²úÎï(½«ÈÝÆ÷ÄÚµÄËùÓÐÎïÖʼÇ×÷ ·õÓý²úÎï)ÖÃÓÚÀëÐĹÜÖУ¬300gÀëÐÄ2·ÖÖÓ£¬ÎüÈ¥ÉϲãÒºÌ壬ÔÙÒÔÏàͬ·½Ê½ÀëÐÄ2´Î¡£·ÖÀ븴ºÏÎïÈ¥³ý·õÓýÌåϵÖÐδ½áºÏµÄϸ¾úÔÉúÖÊÌåºó£¬ÓÃÁ÷ʽϸ°ûÒǽøÐÐ·Ö Ñ¡¡£ÓÃFACSAria II (Becton Dickinson)ͨ¹ýÂÌɫӫ¹âµ°°×½øÐзÖÑ¡£¬ÊÕ¼¯·¢ÂÌɫӫ¹âµÄ H1299-tet on_PAD4ϸ°ûÓëϸ¾úÔÉúÖÊÌåµÄ¸´ºÏÎï¡£»ñµÃ¿¹ÌåÐòÁн«·ÖÑ¡³öµÄ¸´ºÏÎïÓÃEasyPure Plasmid MiniPre Kit(Transgen) °´ÕÕÊÔ¼ÁºÐµÄ²Ù×÷²½ÖèÌáÈ¡±í´ï¿¹ÌåµÄÖÊÁ££¬½«ÌáÈ¡µÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§ ¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£´ÓÑôÐÔ ×ª»¯×ÓÖÐÌáÈ¡ÖÊÁ££¬½øÐвâÐò£¬½á¹ûµÃµ½SEQ ID NO :1ËùʾµÄÄ¿µÄ¿¹ÌåµÄ±àÂë»ùÒòÐòÁУ¬Ëµ Ã÷±¾·¢Ã÷·½·¨Äܹ»É¸Ñ¡µÃµ½ÕýÈ·µÄ¿¹Ìå¡£ÔÙͨ¹ý»ùÒò¹¤³Ì±í´ïºÍ´¿»¯µÃµ½Ä¿µÄ¿¹Ì塣ͳ¼Æ¸»¼¯Ð§Âʽ«·ÖÑ¡³öµÄ¸´ºÏÎïÓÃEasyPure Plasmid MiniPre Kit(Transgen) °´ÕÕÊÔ¼ÁºÐµÄ²Ù×÷²½ÖèÌáÈ¡±í´ï¿¹ÌåµÄÖÊÁ££¬½«ÌáÈ¡µÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§ ¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Ëæ»úÌô È¡48¸öת»¯×Ó£¬²ÉÓþúÂäPCR¼ø¶¨¸»¼¯ºóµÄM18´¿¶È£¬ÔÙͳ¼Æ¸»¼¯Ð§ÂÊ¡£¸»¼¯Ð§ÂʵļÆËã ¹«Ê½¸»¼¯ºóµÄM18´¿¶È/¸»¼¯Ç°µÄM18´¿¶È¡£¼ø¶¨ÒýÎïÐòÁÐ(M18ÌØÒìÒýÎï)ÈçÏÂ5¡¯ -ATATGCTAGCGATATTCAGATGACACAGACT-3¡¯ £»5 ¡¯ -GCGTTTGCCATCTTTTCATAATCAAAATCACC-3¡¯¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûȡƽ¾ùÊý¡£½á¹ûÈçͼ5Ëùʾ¡£µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔÉúÖÊÌåµÄ´¿¶ÈΪ 0. ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ2%£¬Á÷ʽ·ÖÑ¡µÄ¸»¼¯Ð§ÂÊΪ20±¶¡£µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ ÒºÖÐչʾM18ϸ¾úÔÉúÖÊÌåµÄ´¿¶ÈΪ5%ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ65.6%£¬Á÷ʽ·ÖÑ¡µÄ¸»¼¯ ЧÂÊΪ13±¶¡£µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£
µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£×ÛºÏʵÑé(Ò»)ºÍ(¶þ)£¬½á¹û±íÃ÷£¬µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔ ÉúÖÊÌåÊýĿռËùÓÐÔÉúÖÊÌåÊýÄ¿µÄ0. 1 %ʱ£¬ÌÔÑ¡±íÏÖ³ö¸üºÃµÄ¸»¼¯Ð§ÂÊ£¬Îª64±¶¡£µ±ÓÃÓÚ ÊµÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔÉúÖÊÌåÊýĿռËùÓÐÔÉúÖÊÌåÊýÄ¿µÄ5%ʱ£¬Á÷ʽ·ÖÑ¡ ÓµÓбÈÌÔÑ¡¸üÓÅÒìµÄ¸»¼¯Ð§ÂÊ£¬Á÷ʽ·ÖÑ¡µÄ¸»¼¯Ð§ÂÊΪ13±¶£¬ÌÔÑ¡µÄ¸»¼¯Ð§ÂÊΪ5±¶¡£ÌÔÑ¡±ÈÁ÷ʽ·ÖÑ¡¸üÈÝÒײÙ×÷£¬²»ÐèÒª½øÐи´ÔÓµÄÁ÷ʽ·ÖÑ¡£¬²¢ÇÒÄܹ»»ØÊÕ¸ü¶àµÄ ±àÂ뿹Ìå»ùÒòµÄÖÊÁ££¬²»ÐèÒª·ÖÑ¡ºóPCR»ØÊ׿¹Ìå»ùÒò£¬¿ÉÒÔÖ±½Óµçת»¯Ï¸¾ú»ØÊÕÀ©ÔöÖÊ Á£¡£µ±ÌØÒ쿹Ìå±ÈÀý´ïµ½Ò»¶¨ÖµÊ±£¬Á÷ʽ¸üÈÝÒ×ͨ¹ýÇ׺ÍÁ¦µÄÇ¿Èõ½«¸ßÇ׺ÍÁ¦µÄ¿¹ÌåѸËÙ µÄɸѡ¸»¼¯³öÀ´¡£(Èý)ÌÔÑ¡·¨ºÍÁ÷ʽ·ÖÑ¡·¨½áºÏ½«Õ¹Ê¾26-10¿¹ÌåµÄϸ¾úÔÉúÖÊÌåµÄÐü¸¡ÒºÓëչʾM18µÄϸ¾úÔÉúÖÊÌåµÄÐü¸¡Òº »ìºÏ£¬µÃµ½»ìºÏÐü¸¡Òº£¬Ê¹»ìºÏÐü¸¡ÒºÖÐչʾM18µÄϸ¾úÔÉúÖÊÌåÓëչʾ26-10¿¹ÌåµÄϸ¾ú ÔÉúÖÊÌåµÄÊýÄ¿±ÈΪ1 1000»ò1 104£¬È»ºó½«»ìºÏÐü¸¡Òº·Ö±ð½øÐÐÈçÏÂɸѡ¡£(1) Ò»ÂÖÌÔÑ¡ºÍÒ»ÂÖÁ÷ʽ·ÖÑ¡²½Öè1 °´ÕÕʵÑé(Ò»)ÖÐËùÊö·½·¨½øÐÐÌÔѡɸѡ£¬´Óɸѡ²úÎïÖлØÊÕ±í´ï¿¹ÌåµÄ ÖÊÁ££¬½«»ØÊյıí´ï¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿ ²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Í³¼Æ¸»¼¯Ð§ÂÊ¡£²½Öè2 ½«²½Öè1µÃµ½µÄÑôÐÔת»¯×ÓÖÆ³Éϸ¾úÔÉúÖÊÌ壬ÔÙ°´ÕÕʵÑé(¶þ)ÖÐËùÊö ·½·¨½øÐÐÁ÷ʽ·ÖÑ¡¡£½«·ÖÑ¡µÃµ½µÄ¸´ºÏÎï°´ÕÕʵÑé(¶þ)ÖÐËùÊö·½·¨½øÐи»¼¯Ð§ÂÊͳ¼Æ¡£(2) ¶þÂÖÌÔÑ¡ºÍÒ»ÂÖÁ÷ʽ·ÖÑ¡²½Öè1 °´ÕÕʵÑé(Ò»)ÖÐËùÊö·½·¨½øÐÐÌÔѡɸѡ£¬´Óɸѡ²úÎïÖлØÊÕ±í´ï¿¹ÌåµÄ ÖÊÁ££¬½«»ØÊյıí´ï¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿ ²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Í³¼Æ¸»¼¯Ð§ÂÊ¡£²½Öè2:½«²½Öè1µÃµ½µÄÑôÐÔת»¯×ÓÖÆ³Éϸ¾úÔÉúÖÊÌ壬°´ÕÕʵÑé(Ò»)ÖÐËùÊö ·½·¨½øÐÐÌÔѡɸѡ£¬´Óɸѡ²úÎïÖлØÊÕ±í´ï¿¹ÌåµÄÖÊÁ££¬½«»ØÊյıí´ï¿¹ÌåµÄÖÊÁ£µçתÓÚ E. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ù ÉÏɸѡת»¯×Ó¡£Í³¼Æ¸»¼¯Ð§ÂÊ¡£²½Öè3 ½«²½Öè2µÃµ½µÄÑôÐÔת»¯×ÓÖÆ³Éϸ¾úÔÉúÖÊÌ壬ÔÙ°´ÕÕʵÑé(¶þ)ÖÐËùÊö ·½·¨½øÐÐÁ÷ʽ·ÖÑ¡¡£½«·ÖÑ¡µÃµ½µÄ¸´ºÏÎï°´ÕÕʵÑé(¶þ)ÖÐËùÊö·½·¨½øÐи»¼¯Ð§ÂÊͳ¼Æ¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûÈçͼ6Ëùʾ¡£½á¹û±íÃ÷£¬µ±ÑùÆ·ÖÐչʾM18µÄϸ¾úÔÉúÖÊÌåµÄ´¿¶ÈΪ0. ʱ£¬Í¨¹ýÒ»ÂÖÌÔѡɸ Ñ¡£¬M18¿¹ÌåµÄ´¿¶ÈΪ5. 1 %£¬¸»¼¯Ð§ÂÊΪ51±¶£»È»ºóͨ¹ýÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬M18¿¹ÌåµÄ´¿¶È ÄÜ´ïµ½65. 6% £»¡ªÂÖÌÔÑ¡¼ÓÉÏÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬×ܹ²¸»¼¯ÁË 656±¶£¬´ïµ½ÁËÃ÷ÏԵĸ»¼¯Ð§¹û¡£ µ±ÑùÆ·ÖÐչʾM18ϸ¾úÔÉúÖÊÌåµÄ´¿¶ÈΪ0.01%ʱ£¬Á½ÂÖÌÔѡɸѡºó£¬M18¿¹ÌåµÄ´¿¶ÈΪ 6. 25%£¬¸»¼¯Ð§ÂÊΪ625±¶£»¸»¼¯²úÎï½Ó×ÅÔÙ½øÐÐÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬Ôò¸»¼¯²úÎïÖÐM18´¿¶ÈΪ 72.9%£¬Í¨¹ýÁ½ÂÖÌÔÑ¡ºÍÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬×ܹ²»ñµÃÁË > 7200±¶µÄ¸»¼¯Ð§¹û¡£´Ë½á¹û³ä·ÖµÄ ˵Ã÷Á˱¾·¢Ã÷·½·¨Äܹ»ÓÐЧµØÉ¸Ñ¡ÌØÒìʶ±ðÈËϸ°û±íÃæ¿¹ÔµÄ¿¹Ìå¡£±¾·¢Ã÷²ÉÓÃÁËÁ½²½·¨µÄ²ßÂÔÀ´¸»¼¯Ï¸¾úÔÉúÖÊÌ壬Ëü½áºÏÁËÌÔÑ¡ºÍÁ÷ʽ·ÖÑ¡µÄÓÅ µã£¬Í¬Ê±ÓÖÃÖ²¹ÁËÏ໥µÄȱµã£¬¿É´ó´óÌá¸ßɸѡЧÂÊ¡£µ±ÌØÒ쿹ÌåŨ¶È 1000ʱ£¬²ÉÓÃ
17ÌÔÑ¡À´¸»¼¯ÒÔÔö¼ÓÌØÒ쿹ÌåµÄ±ÈÀý¡£È»ºóÀûÓÃÁ÷ʽµÄ¶¨Á¿·ÖÑ¡ÄÜÁ¦£¬½«¾ßÓиü¸ßÇ׺ÍÁ¦µÄ ¿¹Ì帻¼¯³öÀ´¡£
ȨÀûÒªÇó
Ò»ÖÖɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»2)½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ÓÚËùÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔµÄÏ໥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ½«ËùÊö½áºÏÎï´Ó·õÓýÌåϵÖзÖÀë³öÀ´£»4)´Ó²½Öè3)µÃµ½µÄ½áºÏÎïÖзÖÀëµÃµ½ÓëչʾÓÚÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ÌØÒìÐÔ½áºÏµÄÄ¿µÄµ°°×»òÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£
2.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Ëù Êö·õÓýÌåϵµÄPHֵΪ5. 0-7. 5¡£
3.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Ëù Êö·õÓýÌåϵµÄ PH ֵΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0£¬7. 3 »ò 7. 5¡£
4.¸ù¾ÝȨÀûÒªÇó1-3ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þÊÇ Î¶ÈΪ30-37¡ãCºÍʱ¼äΪ0. 5-2Сʱ£»ËùÊöζȾßÌåΪ30¡ãC»ò37¡ãC£¬ËùÊöʱ¼ä¾ßÌåΪ0. 5С ʱ»ò1Сʱ»ò2Сʱ¡£
5.¸ù¾ÝȨÀûÒªÇó1-4ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬²½Öè3)ÖУ¬½«ËùÊö½áºÏÎï´Ó·õÓý ÌåϵÖзÖÀë³öÀ´µÄ²½ÖèÊÇ£¬Ê×ÏÈʹÓÃÆ½°åÌÔÑ¡·¨É¸Ñ¡£¬È»ºóʹÓÃÁ÷ʽ·ÖÑ¡·¨·ÖÑ¡¡£
6.¸ù¾ÝȨÀûÒªÇó5ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬Ê¹ÓÃÁ÷ʽ·ÖÑ¡·¨µÄ²½ÖèΪÊ×ÏÈ´ÓËùÊö·õ ÓýÌåϵÖÐÈ¥³ýδͬËùÊöÕæºËϸ°ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔÉúÖÊÌ壬ÔÙͨ¹ýÁ÷ʽϸ°ûÒÇɸ Ñ¡£¬ÊÕ¼¯ËùÊöÕæºËϸ°ûÓëÔÉúÖÊÌå·¢ÉúÌØÒìÐÔ½áºÏµÄ½áºÏÎï¡£
7.¸ù¾ÝȨÀûÒªÇó6ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδͬËùÊöÕæºËϸ °ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔÉúÖÊÌåµÄ²½ÖèΪ½«ËùÊöµÄ·õÓýÌåϵ³£ÎÂ300gÀëÐÄ1. 5-3·Ö ÖÓºó£¬ÊÕ¼¯³Áµí£¬ÆúÈ¥ÉÏÇå¡£
8.¸ù¾ÝȨÀûÒªÇó1-7ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬²½Öè1)ÖУ¬ËùÊö½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ°ûĤ±íÃæÊÇÓɰüÀ¨Èçϲ½ÖèµÄ·½·¨ ÖÆ±¸µÃµ½µÄ½«º¬ÓÐËùÊöÄ¿±êµ°°×±àÂë»ùÒòµÄÖØ×é±í´ïÔØÌåתÈëËùÊöÕæºËϸ°ûÖУ¬µÃµ½ÖØ ×éÕæºËϸ°û£¬ÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬µÃµ½ËùÊö±íÃæÕ¹Ê¾ÓÐÄ¿±ê µ°°×µÄÕæºËϸ°û£»²½Öè2)ÖУ¬½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæµÄ·½·¨°üÀ¨Èç ϲ½Ö轫´ýɸѡµ°°×µÄ±àÂë»ùÒò²åÈëϸ¾ú±í´ïÔØÌåÖУ¬µÃµ½±í´ïËùÊö´ýɸѡµ°°×µÄÖØ×é ÔØÌ壬½«ËùÊö±í´ï´ýɸѡµ°°×µÄÖØ×éÔØÌåתÈëËÞÖ÷ϸ¾ú£¬µÃµ½ÖØ×éϸ¾ú£¬ÅàÑøËùÊöÖØ×éϸ¾ú ²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬ÔÙÌáÈ¡ÖØ×éϸ¾úµÄÔÉúÖÊÌ壬µÃµ½ËùÊö±íÃæÕ¹Ê¾Óдýɸѡµ° °×µÄϸ¾úÔÉúÖÊÌå¡£
9.¸ù¾ÝȨÀûÒªÇó1-8ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöº¬ÓÐËùÊöÄ¿±êµ°°×µÄ±àÂë »ùÒòµÄÖØ×éÔØÌåÊÇÊÜËÄ»·Ëص÷¿ØµÄÖØ×éÔØÌ壻ËùÊöÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØ ÌåµÄ±í´ïµÄ·½·¨Îª½«²åÈëÍâÔ´»ùÒòºóµÄÕæºË±í´ïÔØÌåתÈëËùÊöÕæºËϸ°û£¬²¢ÓÃËÄ»·ËØÓÕµ¼ËùÊöÕæºËϸ°û±í´ïÄ¿±êµ°°×¡£
10.¸ù¾ÝȨÀûÒªÇó1-9ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöËÞÖ÷ϸ¾úÖл¹×ªÈëÓÃÓÚͨ¹ýÓ«¹â ÐźÅɸѡÔÉúÖÊÌåµÄÓ«¹âµ°°×±í´ïÔØÌå¡£ËùÊöÓ«¹âµ°°×±í´ïÔØÌå¿ÉÒÔÊÇÔÚϸ¾úÖбí´ïÈκΠÑÕɫӫ¹âµ°°×ÖʵÄÔØÌ壬ÓÅѡΪPBAD30-KmR-GFPmut2¡£
11.¸ù¾ÝȨÀûÒªÇó1-10ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöÄ¿±êµ°°×µÄ±àÂë»ùÒò ÊÇÈËÔ´»¯µÄ£»ËùÊöÕæºËϸ°ûÊÇÈË·ÇСϸ°û·Î°©Ï¸°ûÖêH1299 £»ËùÊöÕæºË±í´ïÔØÌåÎªÕæºËϸ °ûĤ±íÃæÕ¹Ê¾ÔØÌ壻ËùÊöÕæºËϸ°ûĤ±íÃæÕ¹Ê¾ÔØÌåÊǺËÜÕËáÐòÁÐÊÇSEQ ID 6ËùʾµÄÔØÌå pUHD10-3-display¡£
12.¸ù¾ÝȨÀûÒªÇó1-11ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöËÞÖ÷ϸ¾úΪ´ó³¦¸Ë¾ú£¬ÓŠѡΪ E.coli Jude-I0
13.¸ù¾ÝȨÀûÒªÇó1-12ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö²½Öè4)ÖУ¬ËùÊö´Ó½áºÏÎï ÖзÖÀëµÃµ½Ä¿µÄµ°°×»òÄ¿µÄµ°°×µÄ±àÂë»ùÒòµÄ·½·¨°üÀ¨Èçϲ½Öè´ÓËùÊö½áºÏÎïÖÐÌáÈ¡Ëù Êö±í´ïÄ¿µÄµ°°×µÄÖØ×éÔØÌ壬¶ÔÖØ×éÔØÌå½øÐвâÐò£¬µÃµ½ËùÊöÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£
14.Ò»ÖÖ¸¨Öú¼ø¶¨µ°°×ÊÇ·ñÓëÄ¿±êµ°°×½áºÏµÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»2)½«´ý¼ø¶¨µ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдý¼ø¶¨ µ°°×µÄϸ¾úÔÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ÓÚËù ÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔµÄÏà »¥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ¼ì²â·õÓýµÄÌåϵÖÐÊÇ·ñ º¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÈôº¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×ÓëËùÊöÄ¿±êµ°°×½á ºÏ£¬Èô²»º¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×²»ÓëËùÊöÄ¿±êµ°°×½áºÏ¡£
15.Ò»ÖÖÓÃÓÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄÊÔ¼ÁºÐ£¬ÓÉÕæºËϸ°û¡¢ÕæºËϸ°û±í´ïÔØ Ìå¡¢ÓÃÓÚÖÆ±¸ÔÉúÖÊÌåµÄϸ¾ú¡¢ÔÉúÖÊÌåÕ¹Ê¾ÔØÌå¡¢ÔÚÔÉúÖÊÌåÖбí´ïÓ«¹âµ°°×ÒÔ±ãÓÚɸѡ µÄÔØÌå×é³É¡£
16.¸ù¾ÝȨÀûÒªÇó15ËùÊöµÄÊÔ¼ÁºÐ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöÕæºËϸ°ûΪÈË·ÇСϸ°û·Î°© ϸ°ûÖêH1299 £»ËùÊöÕæºËϸ°û±í´ïÔØÌåΪpUHDlO-3-display £»ËùÊöϸ¾úΪ´ó³¦¸Ë¾ú¾úÖê Jude-I £»ËùÊö±í´ïÓ«¹âµ°°×µÄÔØÌåΪpBAD30-KmR-GFPmut2¡£
17.ȨÀûÒªÇó15-16ËùÊöÊÔ¼ÁºÐÔÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×ÖеÄÓ¦Óá£
18.ϸ¾úÔÉúÖÊÌåչʾ·½·¨ÔÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×ÖеÄÓ¦Óá£
È«ÎÄÕªÒª
±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖɸѡ¿¹ÌåµÄ·½·¨¡£¸Ã·½·¨°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»2)½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔÉúÖÊÌå¿â¡£±¾·¢Ã÷ÌṩÁËÀûÓÃAPExչʾ¼¼ÊõÓ¦ÓÃÓÚÒÔÍêÕûµÄÈËϸ°ûΪ¿¹ÔÉ¸Ñ¡ÌØÒìʶ±ðÈËϸ°û±íÃæ¿¹ÔµÄ¿¹ÌåµÄÒ»ÖÖɸѡ·½·¨¡£APExϸ¾úչʾϵͳӵÓÐÓëÊɾúÌåչʾϵͳÏ൱´óСµÄ¿¹Ìå¿â(¡Ý109)£¬²¢ÇÒ¾ßÓÐչʾÍêÕûµÄIgG¿¹ÌåµÄÄÜÁ¦¡£´Ë·½·¨µÄ½¨Á¢£¬ÓÐÖúÓÚɸѡ¸ü¶àʶ±ðϸ°û±íÃæ·Ö×Ó±ê¼ÇµÄ¿¹Ì壬¶Ô¼²²¡Õï¶ÏºÍÖÎÁƶ¼½«Æðµ½¾Þ´óµÄÍÆ¶¯×÷Óá£
Îĵµ±àºÅG01N33/53GK101948534SQ20101025736
¹«¿ªÈÕ2011Äê1ÔÂ19ÈÕ ÉêÇëÈÕÆÚ2010Äê8ÔÂ19ÈÕ ÓÅÏÈȨÈÕ2010Äê8ÔÂ19ÈÕ
·¢Ã÷Õߺ¼º£Ó¢, Çñ¿¡¿µ ÉêÇëÈË:Öйú¿ÆÑ§ÔºÉúÎïÎïÀíÑо¿Ëù